,AID,AID Version,AID Revision,Panel Member ID,SID,CID,Bioactivity Outcome,Target GI,Target GeneID,Activity Value [uM],Activity Name,Assay Name,Bioassay Type,PubMed ID,RNAi
0,155,1,1,,74764,785,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the rad50 strain,Other,,
1,157,1,1,,74764,785,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mec2-1 strain,Other,,
2,161,1,1,,74764,785,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the sgs1 mgt1 strain,Other,,
3,165,1,1,,74764,785,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the cln2 rad14 strain,Other,,
4,167,1,1,,74764,785,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the bub3 strain,Other,,
5,175,1,1,,74764,785,Inactive,,,,,NCI Yeast Anticancer Drug Screen. Data for the mlh1 rad18 strain,Other,,
6,192,1,1,,74764,785,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
7,200,1,1,,74764,785,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  B16 Melanoma (intraperitoneal) in B6C3F1 mice,Other,,
8,202,1,1,,74764,785,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (subcutaneous) in NU/NU Swiss (nude) mice,Other,,
9,208,1,1,,74764,785,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  HT29;CX-1 Human Adenocarcinoma (MER+) (intrarenal inoculation) in NU/NU BALB/C (nude) mice,Other,,
10,212,1,1,,74764,785,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Colon Carcinoma 38 (subcutaneous) in B6D2F1 (BDF1) mice,Other,,
11,220,1,1,,74764,785,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Mammary Adenocarcinoma CD8F1 (subcutaneous) in CD8F1,Other,,
12,248,1,1,,74764,785,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  L1210 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
13,262,1,1,,74764,785,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (subcutaneous) in NU/NU Swiss (nude) mice,Other,,
14,264,1,1,,74764,785,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Lung LX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
15,294,1,1,,74764,785,Inconclusive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (subcutaneous) in NU/NU Swiss (nude) mice,Other,,
16,296,1,1,,74764,785,Inactive,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  Human Mammary Carcinoma MX-1 Xenograft (intrarenal inoculation) in NU/NU Swiss (nude) mice,Other,,
17,328,1,1,,74764,785,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in B6D2F1 (BDF1) mice,Other,,
18,330,1,1,,74764,785,Active,,,,,NCI In Vivo Anticancer Drug Screen. Data for tumor model  P388 Leukemia (intraperitoneal) in CD2F1 (CDF1) mice,Other,,
19,357,2,1,,11111286,785,Inactive,,,,,AP1 Signaling Pathway,Confirmatory,,
20,410,1,5,,11111286,785,Inactive,73915100.0,1544.0,,,p450-cyp1a2,Confirmatory,,
21,411,2,1,,11111286,785,Inactive,160794.0,,,Potency,qHTS Assay for Inhibitors of Firefly Luciferase,Confirmatory,,
22,421,1,3,,17389853,785,Inactive,,,,,Cell Viability - BJ,Confirmatory,,
23,422,1,5,,17405139,785,Inactive,21464101.0,7532.0,,,HTS for 14-3-3 protein interaction modulators,Screening,,
24,426,1,2,,17389853,785,Active,,,,,Cell Viability - Jurkat,Confirmatory,,
25,427,1,1,,17389853,785,Inconclusive,,,,,Cell Viability - Hek293,Confirmatory,,
26,429,1,5,,17405139,785,Inactive,4261762.0,3326.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
27,429,1,5,,17405139,785,Inactive,154146191.0,3320.0,,,HTS for Tumor Hsp90 Inhibitors,Screening,,
28,433,1,1,,17389853,785,Inactive,,,,,Cell Viability - HepG2,Confirmatory,,
29,434,1,2,,17389853,785,Inactive,,,,,Cell Viability - MRC5,Confirmatory,,
30,435,1,2,,17389853,785,Inconclusive,,,,,Cell Viability - SK-N-SH,Confirmatory,,
31,436,2,1,,17405139,785,Inactive,68565074.0,8314.0,,,HTS for BAP1 Enzyme inhibitors,Screening,,
32,444,1,1,,11111286,785,Inactive,,,,,NFAT Signaling Pathway,Confirmatory,,
33,445,3,1,,11111286,785,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
34,445,3,1,,17389853,785,Inactive,10092619.0,4792.0,,,IkB Signaling,Confirmatory,,
35,446,1,1,,11111286,785,Inactive,,,,,Stat Signaling Pathway,Confirmatory,,
36,447,1,1,,11111286,785,Inconclusive,,,,,O-Glc NAc Transferase (sOGT),Confirmatory,,
37,448,1,2,,11111286,785,Inactive,4325211.0,,,,Schistosoma Mansoni Peroxiredoxins (Prx2),Confirmatory,,
38,450,1,2,,11111286,785,Inactive,66528677.0,2908.0,,,GR-GFP Redistribution,Confirmatory,,
39,451,1,2,,11111286,785,Inactive,66528677.0,2908.0,,,GR-EFC Redistribution,Confirmatory,,
40,526,1,1,,11111286,785,Inactive,,,,,Ubiquitin-GFP Assay,Confirmatory,,
41,530,1,1,,11111286,785,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
42,530,1,1,,17389853,785,Inactive,2499604.0,26414.0,,,JNK3 AlphaScreen Assay,Confirmatory,,
43,540,1,1,,17389853,785,Active,,,,,Cell Viability - N2a,Confirmatory,,
44,541,1,1,,17389853,785,Active,,,,,Cell Viability - NIH 3T3,Confirmatory,,
45,542,1,1,,17389853,785,Active,,,,,Cell Viability - HUV-EC-C,Confirmatory,,
46,543,1,1,,17389853,785,Active,,,,,Cell Viability - H-4-II-E,Confirmatory,,
47,544,2,1,,17389853,785,Active,,,,,Cell Viability - SH-SY5Y,Confirmatory,,
48,545,1,1,,17389853,785,Inconclusive,,,,,Cell Viability - Renal Proximal Tubule,Confirmatory,,
49,546,1,1,,17389853,785,Active,,,,,Cell Viability - Mesenchymal,Confirmatory,,
50,547,1,4,,17405139,785,Inactive,16130533.0,947097.0,,,HTS for inhibitors of bacterial DnaK,Other,,
51,584,1,3,,11111286,785,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
52,584,1,3,,17389853,785,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay with detergent),Confirmatory,,
53,585,1,4,,11111286,785,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
54,585,1,4,,17389853,785,Inactive,119389684.0,,,,Promiscuous and Specific Inhibitors of AmpC Beta-Lactamase (assay without detergent),Confirmatory,,
55,587,1,5,,11111286,785,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Texas Red Spectral Region,Other,,
56,588,1,4,,11111286,785,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Resorufin Spectral Region,Other,,
57,589,1,3,,11111286,785,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in 4-MU Spectral Region,Other,,
58,590,1,3,,11111286,785,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A350 Spectral Region,Other,,
59,591,1,4,,11111286,785,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A488 Spectral Region,Other,,
60,592,1,6,,11111286,785,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in A647 Spectral Region,Other,,
61,593,1,4,,11111286,785,Inconclusive,,,,,qHTS Assay for Spectroscopic Profiling in Fluorescein Spectral Region,Other,,
62,594,1,4,,11111286,785,Inactive,,,,,qHTS Assay for Spectroscopic Profiling in Rhodamine Spectral Region,Confirmatory,,
63,595,1,3,,11111286,785,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
64,595,1,3,,17389853,785,Inactive,,,,,qHTS Assay for Disrupters of an Hsp90 Co-Chaperone Interaction,Confirmatory,,
65,596,1,2,,11111286,785,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
66,596,1,2,,17389853,785,Inactive,92096784.0,4137.0,,,qHTS Assay for Tau Filament Binding,Confirmatory,,
67,597,1,3,,11111286,785,Inactive,,,,,qHTS Assay for Epigenetic Modulators,Confirmatory,,
68,603,1,2,,11111286,785,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
69,603,1,2,,17389853,785,Inactive,,,,,qHTS Assay for Inhibitors of DNA Polymerase III Holoenzyme System,Confirmatory,,
70,605,1,2,,11111286,785,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
71,605,1,2,,17389853,785,Inactive,84028058.0,,,,qHTS Assay for Inhibitors of YjeE,Confirmatory,,
72,607,1,3,,11111286,785,Inactive,82799486.0,5142.0,,,qHTS Assay for Inhibitors of PDE-IV,Confirmatory,,
73,654,1,1,,17389853,785,Inactive,,,,,Cellular Toxicity (caspase-3) HepG2,Confirmatory,,
74,655,1,1,,17389853,785,Inactive,,,,,Cellular Toxicity (caspase-3) Jurkat,Confirmatory,,
75,656,1,1,,17389853,785,Inactive,,,,,Cellular Toxicity (caspase-3) HUV-EC-C,Confirmatory,,
76,657,1,1,,17389853,785,Inactive,,,,,Cellular Toxicity (caspase-3) SHSY5Y,Confirmatory,,
77,658,1,1,,17389853,785,Inactive,,,,,Cellular Toxicity (caspase-3) BJ,Confirmatory,,
78,659,1,1,,17389853,785,Inactive,,,,,Cellular Toxicity (caspase-3) MRC-5,Confirmatory,,
79,660,1,1,,17389853,785,Inactive,,,,,Cellular Toxicity (caspase-3) Mesangial,Confirmatory,,
80,661,1,1,,17389853,785,Inactive,,,,,Cellular Toxicity (caspase-3) SK-N-SH,Confirmatory,,
81,662,1,1,,11111286,785,Inactive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
82,662,1,1,,17389853,785,Inconclusive,,,,,Cell signaling CRE-BLA (Fsk stim),Confirmatory,,
83,663,1,1,,17389853,785,Inconclusive,,,,,Cellular Toxicity (caspase-3) H-4-II-E,Confirmatory,,
84,664,1,1,,17389853,785,Inactive,,,,,Cellular Toxicity (caspase-3) Hek293,Confirmatory,,
85,665,1,1,,17389853,785,Inactive,,,,,Cellular Toxicity (caspase-3) N2a,Confirmatory,,
86,666,1,1,,17389853,785,Inconclusive,,,,,Cellular Toxicity (caspase-3) NIH 3T3,Confirmatory,,
87,667,1,1,,17389853,785,Inactive,,,,,Cellular Toxicity (caspase-3) Renal Proximal Tubule,Confirmatory,,
88,694,1,1,,17405139,785,Inactive,118764400.0,2099.0,,,HTS of LOPAC library for Estrogen Receptor-alpha Coactivator Binding inhibitors,Confirmatory,,
89,732,1,2,,17405139,785,Inactive,,,,,In Vivo Angiogenesis Assay for HTS,Screening,,
90,875,1,2,,17389853,785,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Green Fluorophore),Confirmatory,,
91,879,1,2,,17389853,785,Inactive,3290016.0,6002.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
92,879,1,2,,17389853,785,Inactive,33946324.0,2770.0,,Potency,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Green Fluorophore),Confirmatory,,
93,880,2,1,,17389853,785,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
94,880,2,1,,17389853,785,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
95,880,2,1,,26747267,785,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
96,880,2,1,,26747267,785,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
97,880,2,1,,50105477,785,Inactive,3290016.0,6002.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
98,880,2,1,,50105477,785,Inactive,33946324.0,2770.0,,,qHTS Assay for Inhibitors of RGS12 GoLoco Motif Activity (Red Fluorophore),Confirmatory,,
99,881,2,2,,17389853,785,Inactive,317373425.0,247.0,,Potency,qHTS Assay for Inhibitors of 15-hLO-2 (15-human lipoxygenase 2),Confirmatory,,
100,883,1,3,,11111286,785,Inactive,13699818.0,1559.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C9,Confirmatory,,
101,884,1,2,,17389853,785,Inconclusive,13435386.0,1576.0,1.0,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 3A4,Confirmatory,,
102,885,1,2,,17389853,785,Inactive,13435386.0,1576.0,1.0,Potency,qHTS Assay for Activators of Cytochrome P450 3A4,Confirmatory,,
103,886,1,2,,11111286,785,Active,122921310.0,,1.2589,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
104,886,1,2,,11111286,785,Active,122921311.0,,1.2589,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
105,886,1,2,,17389853,785,Active,122921310.0,,0.3981,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
106,886,1,2,,17389853,785,Active,122921311.0,,0.3981,Potency,"qHTS Assay for Inhibitors of HADH2 (Hydroxyacyl-Coenzyme A Dehydrogenase, Type II)",Confirmatory,,
107,887,1,2,,17389853,785,Inconclusive,1832253.0,246.0,15.8489,Potency,qHTS Assay for Inhibitors of 15-hLO (15-human lipoxygenase),Confirmatory,,
108,889,1,3,,17389853,785,Inactive,1730092.0,840.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-7,Confirmatory,,
109,891,1,2,,11111286,785,Inactive,40805836.0,1565.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2D6,Confirmatory,,
110,892,1,2,,17389853,785,Inactive,159162802.0,,,Potency,qHTS Assay for Inhibitors of BRCT-Phosphoprotein Interaction (Red Fluorophore),Confirmatory,,
111,893,1,2,,17389853,785,Active,122921310.0,,1.2589,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
112,893,1,2,,17389853,785,Active,122921311.0,,1.2589,Potency,"qHTS Assay for Inhibitors of HSD17B4, hydroxysteroid (17-beta) dehydrogenase 4",Confirmatory,,
113,894,2,1,,17389853,785,Active,31542939.0,3248.0,10.0,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
114,894,2,1,,26747267,785,Active,31542939.0,3248.0,5.6234,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
115,894,2,1,,50105477,785,Active,31542939.0,3248.0,7.9433,Potency,qHTS Assay for Inhibitors of HPGD (15-Hydroxyprostaglandin Dehydrogenase),Confirmatory,,
116,895,1,2,,17389853,785,Active,21620132.0,4790.0,10.0,Potency,qHTS Assay for Identification of Small Molecule Antagonists for NFkB Signaling Pathway,Confirmatory,,
117,899,1,2,,11111286,785,Inactive,4503219.0,1557.0,,Potency,qHTS Assay for Inhibitors and Substrates of Cytochrome P450 2C19,Confirmatory,,
118,900,1,3,,17389853,785,Inactive,15431328.0,834.0,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1,Confirmatory,,
119,901,1,2,,17389853,785,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors,Confirmatory,,
120,902,1,2,,17389853,785,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Nonpermissive Temperature,Confirmatory,,
121,910,1,2,,17389853,785,Inconclusive,4504349.0,3043.0,12.5893,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 654 locus,Confirmatory,,
122,912,1,2,,11111286,785,Inconclusive,21392848.0,,12.5893,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
123,912,1,2,,17389853,785,Inconclusive,21392848.0,,,Potency,qHTS Assay for Anthrax Lethal Toxin Internalization,Confirmatory,,
124,914,1,3,,11111286,785,Inconclusive,32879895.0,3091.0,1.9953,Potency,qHTS Assay for Identification of Small Molecule Agonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
125,915,1,3,,11111286,785,Active,32879895.0,3091.0,1.9953,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Hypoxia Response Element Signaling Pathway,Confirmatory,,
126,917,1,3,,17389853,785,Inconclusive,120660324.0,7066.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Agonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
127,918,1,3,,17389853,785,Active,120660324.0,7066.0,12.5893,Potency,qHTS Assay for Identification of Small Molecule Antagonists for Thrombopoietin (TPO) Signaling Pathway,Confirmatory,,
128,921,1,2,,17389853,785,Active,,,25.1189,Potency,Cell Viability - LYMP2-001,Confirmatory,,
129,923,1,2,,17389853,785,Inactive,,,,Potency,qHTS Assay for Allosteric/Competitive Inhibitors of Caspase-1: Spectroscopic Profiling in AFC Spectral Region,Confirmatory,,
130,924,1,2,,17389853,785,Inactive,120407068.0,7157.0,,Potency,qHTS Screen for Compounds that Selectively Target Cancer Cells with p53 Mutations: Cytotoxicity of p53ts Cells at the Permissive Temperature,Confirmatory,,
131,925,1,2,,11111286,785,Inactive,4504349.0,3043.0,,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
132,925,1,2,,17389853,785,Inconclusive,4504349.0,3043.0,39.8107,Potency,qHTS Assay for Modulators of Hemoglobin Beta Chain Splicing,Confirmatory,,
133,926,1,2,,11111286,785,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
134,926,1,2,,17389853,785,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
135,927,1,3,,17389853,785,Inactive,188528692.0,9099.0,,Potency,qHTS Assay for Inhibitors of Ubiquitin-specific Protease USP2a,Confirmatory,,
136,928,1,2,,17389853,785,Inconclusive,21620132.0,4790.0,10.0,Potency,qHTS Assay for Identification of Small Molecule Agonists for NFkB Signaling Pathway,Confirmatory,,
137,930,1,2,,17389853,785,Inactive,4504349.0,3043.0,,Potency,Confirmation and Secondary Assay for Modulators of Hemoglobin Beta Chain Splicing at IVS2 705 locus,Confirmatory,,
138,938,1,2,,11111286,785,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
139,938,1,2,,17389853,785,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Agonists of the Thyroid Stimulating Hormone Receptor: Activators of Intracellular cAMP Concentrations in Parental HEK 293,Confirmatory,,
140,940,1,2,,17405139,785,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
141,940,1,2,,26612686,785,Inactive,31881630.0,5732.0,,,Modulators of the EP2 prostaglandin E2 receptor - Primary Screening,Screening,,
142,943,1,2,,17389853,785,Inactive,18249941.0,25229.0,,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Kinetic Measurement of Intracellular Calcium Response,Confirmatory,,
143,944,1,2,,17389853,785,Inconclusive,18249941.0,25229.0,19.9526,Potency,qHTS Assay for Antagonists of Acetylcholine Muscarinic M1 Receptor: Measurement of IP-One Response,Confirmatory,,
144,945,1,4,,17389853,785,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Inhibitors of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
145,946,1,2,,17389853,785,Inconclusive,,,0.7943,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Dead Cells,Confirmatory,,
146,947,1,2,,17389853,785,Inconclusive,,,31.6228,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-001 - Live Cells,Confirmatory,,
147,948,1,2,,17389853,785,Active,,,31.6228,Potency,Cell Viability - LYMP1-002 - Assay at 16 hr,Confirmatory,,
148,954,1,2,,17389853,785,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Activators of Human Muscle Pyruvate Kinase,Confirmatory,,
149,955,1,2,,17389853,785,Inconclusive,,,25.1189,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Live Cells,Confirmatory,,
150,957,1,2,,17389853,785,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 4.5,Confirmatory,,
151,958,1,2,,17389853,785,Inactive,33286420.0,5315.0,,Potency,qHTS Assay for Inhibitors of Human Muscle Pyruvate Kinase,Confirmatory,,
152,959,1,4,,17389853,785,Inactive,290753097.0,,,Potency,qHTS Validation Assay for Activators of Leishmania Mexicana Pyruvate Kinase,Confirmatory,,
153,960,1,2,,17389853,785,Active,,,12.5893,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-002 - Dead Cells,Confirmatory,,
154,961,1,2,,17389853,785,Active,,,12.5893,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Dead Cells,Confirmatory,,
155,962,1,2,,17389853,785,Active,,,50.1187,Potency,MultiTox-Fluor Cytotoxicity Assay - LYMP1-003 - Live Cells,Confirmatory,,
156,963,1,2,,17389853,785,Active,,,39.8107,Potency,Cell Viability - LYMP1-003 - Assay at 24 hr,Confirmatory,,
157,964,1,2,,17389853,785,Active,,,12.5893,Potency,Cell Viability - LYMP1-003 - Assay at 40 hr,Confirmatory,,
158,965,1,2,,17389853,785,Active,,,39.8107,Potency,Cell Viability - LYMP2-003,Confirmatory,,
159,966,1,2,,17389853,785,Active,,,39.8107,Potency,Cell Viability - LYMP2-004,Confirmatory,,
160,967,1,2,,17389853,785,Active,,,39.8107,Potency,Cell Viability - LYMP2-005,Confirmatory,,
161,968,1,2,,17389853,785,Active,,,50.1187,Potency,Cell Viability - LYMP2-009,Confirmatory,,
162,969,1,2,,17389853,785,Active,,,39.8107,Potency,Cell Viability - LYMP2-011,Confirmatory,,
163,970,1,2,,17389853,785,Inconclusive,,,39.8107,Potency,Cell Viability - LYMP2-013,Confirmatory,,
164,971,1,2,,17389853,785,Active,,,50.1187,Potency,Cell Viability - LYMP2-015,Confirmatory,,
165,972,1,2,,17389853,785,Active,,,39.8107,Potency,Cell Viability - LYMP2-017,Confirmatory,,
166,973,1,2,,17389853,785,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-019,Confirmatory,,
167,974,1,2,,17389853,785,Active,,,50.1187,Potency,Cell Viability - LYMP2-021,Confirmatory,,
168,975,1,2,,17389853,785,Inactive,,,,Potency,Cell Viability - LYMP2-023,Confirmatory,,
169,976,1,2,,17389853,785,Inactive,,,,Potency,Cell Viability - LYMP2-025,Confirmatory,,
170,977,1,2,,17389853,785,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-002,Confirmatory,,
171,978,1,2,,17389853,785,Inconclusive,,,25.1189,Potency,Cell Viability - LYMP2-006,Confirmatory,,
172,979,1,2,,17389853,785,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-007,Confirmatory,,
173,980,1,2,,17389853,785,Active,,,50.1187,Potency,Cell Viability - LYMP2-008,Confirmatory,,
174,981,1,2,,17389853,785,Active,,,39.8107,Potency,Cell Viability - LYMP2-010,Confirmatory,,
175,982,1,2,,17389853,785,Active,,,50.1187,Potency,Cell Viability - LYMP2-012,Confirmatory,,
176,983,1,2,,17389853,785,Inactive,,,,Potency,Cell Viability - LYMP2-014,Confirmatory,,
177,984,1,2,,17389853,785,Inactive,,,,Potency,Cell Viability - LYMP2-016,Confirmatory,,
178,985,1,2,,17389853,785,Inconclusive,,,50.1187,Potency,Cell Viability - LYMP2-018,Confirmatory,,
179,986,1,2,,17389853,785,Active,,,50.1187,Potency,Cell Viability - LYMP2-020,Confirmatory,,
180,987,1,2,,17389853,785,Active,,,39.8107,Potency,Cell Viability - LYMP2-022,Confirmatory,,
181,988,1,2,,17389853,785,Active,,,50.1187,Potency,Cell Viability - LYMP2-024,Confirmatory,,
182,989,1,2,,17389853,785,Inactive,,,,Potency,Cell Viability - LYMP2-026,Confirmatory,,
183,992,1,3,,17389853,785,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Human alpha-Galactosidase at pH 4.5,Confirmatory,,
184,993,1,2,,17389853,785,Active,,,39.8107,Potency,Cell Viability - LYMP1-002 - Assay at 24 hr,Confirmatory,,
185,994,1,2,,17389853,785,Inconclusive,,,31.6228,Potency,Cell Viability - LYMP1-002 - Assay at 40 hr,Confirmatory,,
186,995,1,2,,17389853,785,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay,Confirmatory,,
187,997,1,2,,17389853,785,Inactive,52076901.0,4341833.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Rice alpha-Glucosidase at pH 5.0,Confirmatory,,
188,998,1,2,,17389853,785,Inactive,757912.0,2717.0,,Potency,Counterscreen for Glucocerebrosidase Inhibitors: qHTS Assay for Coffee Bean alpha-Galactosidase at pH 5.9,Confirmatory,,
189,1030,2,1,,17389853,785,Inconclusive,30582681.0,216.0,35.4813,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
190,1030,2,1,,26747267,785,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
191,1030,2,1,,50105477,785,Inactive,30582681.0,216.0,,Potency,qHTS Assay for Inhibitors of Aldehyde Dehydrogenase 1 (ALDH1A1),Confirmatory,,
192,1189,1,5,,48413875,785,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary SingleCellCall Results,Other,,
193,1194,1,3,,48413875,785,Inactive,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Salmonella Mutagenicity,Other,,
194,1199,1,3,,48413875,785,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Mouse Bioassay Results,Other,,
195,1205,1,4,,48413875,785,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary MultiCellCall Results,Other,,
196,1208,1,3,,48413875,785,Active,,,,,DSSTox (CPDBAS) Carcinogenic Potency Database Summary Rat Bioassay Results,Other,,
197,1376,1,2,,46500618,785,Inactive,15608158.0,886069.0,,IC50,Inhibitors of Mycobacterial Glucosamine-1-phosphate acetyl transferase (GlmU),Confirmatory,,
198,1379,1,2,,26747267,785,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
199,1379,1,2,,50105477,785,Inactive,1669525.0,,,Potency,Counterscreen for Luciferase (Kinase-Glo TM) Inhibition,Confirmatory,,
200,1385,2,2,,46500618,785,Inactive,49168602.0,5888.0,,,Homologous recombination - Rad 51,Screening,,
201,1422,1,1,,17405139,785,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
202,1422,1,1,,26612686,785,Active,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
203,1422,1,1,,46500618,785,Inactive,31881630.0,5732.0,,,Inhibitors of the EP2 Prostaglandin E2 Receptor - Primary Screen,Screening,,
204,1452,1,1,,17389853,785,Inactive,154426292.0,239.0,,Potency,qHTS Assay for Inhibitors of 12-hLO (12-human lipoxygenase),Confirmatory,,
205,1454,1,1,,26747267,785,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
206,1454,1,1,,50105477,785,Inactive,66932916.0,5594.0,,Potency,qHTS Assay for Inhibitors of the ERK Signaling Pathway using a Homogeneous Screening Assay; Stimulation with EGF,Confirmatory,,
207,1457,1,1,,17389853,785,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
208,1457,1,1,,26747267,785,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
209,1457,1,1,,50105477,785,Inactive,44888968.0,83523.0,,Potency,qHTS Assay for Identifying the Cell-Membrane Permeable IMPase Inhibitors: Potentiation with Lithium,Confirmatory,,
210,1458,1,1,,17389853,785,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
211,1458,1,1,,26747267,785,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
212,1458,1,1,,50105477,785,Inactive,10937869.0,6607.0,,Potency,qHTS Assay for Enhancers of SMN2 Splice Variant Expression,Confirmatory,,
213,1459,1,1,,50105477,785,Inconclusive,27436948.0,4000.0,11.2202,Potency,Validation of Assay for Modulators of Lamin A Splicing,Confirmatory,,
214,1460,1,3,,26747267,785,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
215,1460,1,3,,50105477,785,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Thioflavin T Binding",Confirmatory,,
216,1461,1,2,,50105477,785,Inactive,46395496.0,387129.0,,Potency,qHTS Assay for Antagonists of the Neuropeptide S Receptor: cAMP Signal Transduction,Confirmatory,,
217,1463,1,1,,26747267,785,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
218,1463,1,1,,50105477,785,Inactive,,,,Potency,"Counterscreen qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
219,1465,1,1,,46500618,785,Inactive,,,,EC50,"Screen for small molecule probes relevant to Friedreich's ataxia, Single Dose and Dose Response",Confirmatory,,
220,1467,1,3,,26747267,785,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
221,1467,1,3,,50105477,785,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors of Human alpha-Galactosidase at pH 4.5.,Confirmatory,,
222,1468,1,1,,26747267,785,Inactive,92096784.0,4137.0,,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
223,1468,1,1,,50105477,785,Inconclusive,92096784.0,4137.0,7.9433,Potency,"qHTS for Inhibitors of Tau Fibril Formation, Fluorescence Polarization",Confirmatory,,
224,1469,1,1,,17389853,785,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
225,1469,1,1,,26747267,785,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
226,1469,1,1,,50105477,785,Inactive,189491771.0,7068.0,,Potency,qHTS for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
227,1471,2,1,,11111286,785,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
228,1471,2,1,,17389853,785,Active,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
229,1471,2,1,,26747267,785,Inactive,90903231.0,3064.0,,,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Cytoprotection (ATP),Confirmatory,,
230,1476,2,1,,17389853,785,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
231,1476,2,1,,26747267,785,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
232,1476,2,1,,50105477,785,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (without detergent),Confirmatory,,
233,1477,1,1,,17389853,785,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
234,1477,1,1,,26747267,785,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
235,1477,1,1,,50105477,785,Inactive,,,,Potency,qHTS Assay for Compounds Blocking the Interaction Between CBF-beta and RUNX1 for the Treatment of Acute Myeloid Leukemia,Confirmatory,,
236,1478,2,1,,17389853,785,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
237,1478,2,1,,26747267,785,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
238,1478,2,1,,50105477,785,Inactive,281307097.0,,,Potency,qHTS Assay for Promiscuous and Specific Inhibitors of Cruzain (with detergent),Confirmatory,,
239,1479,1,2,,17389853,785,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
240,1479,1,2,,26747267,785,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
241,1479,1,2,,50105477,785,Inactive,189491771.0,7068.0,,Potency,Total Fluorescence Counterscreen for Inhibitors of the Interaction of Thyroid Hormone Receptor and Steroid Receptor Coregulator 2,Confirmatory,,
242,1487,1,1,,17389853,785,Inconclusive,27436948.0,4000.0,2.8184,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
243,1487,1,1,,50105477,785,Inconclusive,27436948.0,4000.0,7.9433,Potency,qHTS Assay for Modulators of Lamin A Splicing,Confirmatory,,
244,1490,2,1,,17389853,785,Inconclusive,10954339.0,,44.6684,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
245,1490,2,1,,26747267,785,Inactive,10954339.0,,,Potency,qHTS Assay for Inhibitors of Bacillus subtilis Sfp phosphopantetheinyl transferase (PPTase),Confirmatory,,
246,1511,1,3,,46500618,785,Inactive,487738.0,3757.0,,,Primary cell-based high-throughput screening assay for identification of compounds that protect hERG from block by proarrhythmic agents,Screening,,
247,1519,1,3,,26747267,785,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
248,1519,1,3,,50105477,785,Inactive,,,,Potency,qHTS Assay for Lipid Storage Modulators,Confirmatory,,
249,1529,1,1,,46500618,785,Inactive,42794767.0,4215.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase3 Wildtype",Screening,,
250,1530,1,1,,46500618,785,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 MEK Kinase 2 mutant",Screening,,
251,1531,1,1,,46500618,785,Inactive,22035600.0,5871.0,,,"Multiplex HTS Assay for Inhibitors of MEK Kinase PB1 Domains, specifically MEK5 binding to MEK Kinase 2 Wildtype",Screening,,
252,1532,1,1,,46500618,785,Inactive,,,,,Rml C and D inhibition 384-well mixture HTS,Screening,,
253,1554,1,1,,46500618,785,Inactive,,,,,MLPCN Ras selective lethality-BJeLR viability,Screening,,
254,1621,1,2,,46500618,785,Inactive,,,,IC50,A Cell Based Assay for the Identification of Lead Compounds with Anti-Viral Activity Against West Nile Virus,Confirmatory,,
255,1626,1,2,,46500618,785,Inactive,,,,IC50,High Throughput Screen to Identify Inhibitors of Mycobacterium tuberculosis H37Rv,Confirmatory,,
256,1662,1,2,,46500618,785,Inactive,15675770.0,901648.0,,,MLPCN Streptokinase Expression Inhibition,Screening,,
257,1663,1,2,,46500618,785,Inactive,,,,,MLPCN Platelet Activation -Dense Granule Release,Screening,,
258,1672,1,3,,46500618,785,Inactive,6680530.0,16518.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit/block inward-rectifying potassium ion channel Kir2.1,Screening,,
259,1688,1,1,,17389853,785,Inactive,90903231.0,3064.0,,Potency,qHTS Multiplex Assay to Identify Dual Action Probes in a Cell Model of Huntington: Aggregate Formation (GFP),Confirmatory,,
260,1705,1,2,,50105477,785,Inactive,6980812.0,,,Potency,qHTS Validation Assay for Inhibitors of the Human Apurinic/apyrimidinic  Endonuclease 1 (APE1),Confirmatory,,
261,1707,1,3,,50105477,785,Inactive,,,,Potency,Counterscreen for APE1 Inhibitors: Fluorescent Dye Displacement Validation Assay,Confirmatory,,
262,1708,1,3,,50105477,785,Inconclusive,405898.0,,10.0,Potency,Counterscreen for APE1 Inhibitors: qHTS Validation Assay for Inhibitors of Endonuclease IV,Confirmatory,,
263,1766,1,1,,17389853,785,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
264,1766,1,1,,17389853,785,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
265,1766,1,1,,26747267,785,Inconclusive,18860839.0,4221.0,6.3096,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
266,1766,1,1,,26747267,785,Inconclusive,56550039.0,4297.0,6.3096,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
267,1766,1,1,,50105477,785,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
268,1766,1,1,,50105477,785,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Fluorescein Labeled MLL-derived Peptide,Confirmatory,,
269,1768,1,1,,17389853,785,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
270,1768,1,1,,17389853,785,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
271,1768,1,1,,26747267,785,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
272,1768,1,1,,26747267,785,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
273,1768,1,1,,50105477,785,Inactive,18860839.0,4221.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
274,1768,1,1,,50105477,785,Inactive,56550039.0,4297.0,,Potency,qHTS Assay for Inhibitors Targeting the Menin-MLL Interaction in MLL Related Leukemias: Competition With Texas Red Labeled MLL-derived Mutant Peptide,Confirmatory,,
275,1813,1,2,,46500618,785,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - inhibitors,Screening,,
276,1814,1,2,,46500618,785,Inactive,,,,,MLPCN Alpha-Synuclein 5'UTR - 5'-UTR binding - activators,Screening,,
277,1815,1,1,,50105477,785,Active,,,8.9125,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 7G8,Confirmatory,,
278,1816,1,1,,50105477,785,Inconclusive,,,10.0,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line GB4,Confirmatory,,
279,1828,2,1,,50105477,785,Inconclusive,,,,,qHTS for Inhibitors of Plasmodium falciparum proliferation: Summary,Summary,,
280,1832,2,1,,46500618,785,Inactive,55976631.0,178296.0,,,MLPCN maternal gene expression-MEX-5 TCR-2 binding assay-Primary Screen,Screening,,
281,1850,2,1,,46500618,785,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella typhi,Confirmatory,,
282,1863,2,1,,46500618,785,Inactive,,,,IC50,A small molecule screen for inhibitors of the PhoP regulon in Salmonella Typhimurium,Confirmatory,,
283,1865,1,1,,26747267,785,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
284,1865,1,1,,50105477,785,Inactive,,,,Potency,Quantitative High-Throughput Screen for Regulators of Epigenetic Control,Confirmatory,,
285,1875,2,1,,46500618,785,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Polyadenylation,Screening,,
286,1876,1,1,,50105477,785,Active,,,11.2202,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line 3D7,Confirmatory,,
287,1877,1,1,,50105477,785,Inconclusive,,,11.2202,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line D10,Confirmatory,,
288,1882,1,1,,50105477,785,Inconclusive,,,12.5893,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line Dd2,Confirmatory,,
289,1883,1,1,,50105477,785,Active,,,12.5893,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line W2,Confirmatory,,
290,1885,2,1,,46500618,785,Inactive,,,,,Luminescence Cell-Based/Microorganism Primary HTS to Identify Inhibitors of T.Cruzi Replication,Screening,,
291,1886,1,1,,50105477,785,Active,,,12.5893,Potency,qHTS for differential inhibitors of proliferation of Plasmodium falciparum line HB3,Confirmatory,,
292,1899,1,3,,46500618,785,Inactive,83779224.0,,,,TR-FRET-based primary biochemical high-throughput screening assay to identify inhibitors of Hepatitis C Virus (HCV) core protein dimerization,Screening,,
293,1903,2,3,,46500618,785,Active,297591903.0,29031019.0,7.76,IC50,Identification of SV40 T antigen inhibitors: A route to novel anti-viral reagents,Confirmatory,,
294,1906,1,3,,46500618,785,Inactive,55958172.0,,,,QFRET-based counterscreen for PFM18AAP inhibitors: biochemical high throughput screening assay to identify inhibitors of the Cathepsin L proteinase (CTSL1).,Screening,,
295,1910,1,2,,46500618,785,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Transcriptional Activators of Hypoxia-Inducible Factor Pathway,Screening,,
296,1947,1,2,,46500618,785,Inactive,21595511.0,226016.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the serine hydrolase family member Fam108B.,Screening,,
297,1948,1,1,,17389853,785,Active,,,12.5893,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
298,1948,1,1,,26747267,785,Inconclusive,,,6.3096,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
299,1948,1,1,,50105477,785,Active,,,10.0,Potency,qHTS Assay for Compounds that Induce Erasure of Genomic Imprints,Confirmatory,,
300,1950,1,3,,46500618,785,Inactive,23893623.0,3783709.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the Epstein-Barr virus nuclear antigen 1 (EBNA-1).,Screening,,
301,1956,1,1,,46500618,785,Inactive,,,,Conc @ Max Fold Increase,A high-throughput screen to identify small molecule compounds that augment HSV replication,Confirmatory,,
302,1962,1,2,,46500618,785,Inactive,68476498.0,,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of tRNA 2'-phosphotransferase (TPT1).,Screening,,
303,1967,1,1,,85231080,785,Inconclusive,4505907.0,5376.0,21.3313,Potency,qHTS Assay for Modulators of Human Peripheral Myelin Protein 22 (PMP22) Expression/Activity,Confirmatory,,
304,1974,1,2,,46500618,785,Active,4758484.0,9446.0,,,Fluorescence polarization-based counterscreen for RBBP9 inhibitors: primary biochemical high throughput screening assay to identify inhibitors of the oxidoreductase glutathione S-transferase omega 1(GSTO1).,Screening,,
305,1987,1,2,,46500618,785,Inactive,37589898.0,5536.0,,,Fluorescence-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase 5 (PP5).,Screening,,
306,2016,1,3,,46500618,785,Inactive,1302091.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ MEP2_MLPCN.,Screening,,
307,2023,1,3,,46500618,785,Inactive,486173.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ LAP4_MLPCN.,Screening,,
308,2025,1,3,,46500618,785,Inactive,536029.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ RPL19A_MLPCN.,Screening,,
309,2029,1,3,,46500618,785,Inactive,171229.0,,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ CIT2_MLPCN.,Screening,,
310,2052,2,1,,46500618,785,Inactive,124486680.0,16408.0,,,HTS for developing T Cell Immune Modulators,Screening,,
311,2057,1,2,,46500618,785,Inactive,78070770.0,4170.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of myeloid cell leukemia sequence 1 (MCL1) interactions with BIM-BH3 peptide.,Screening,,
312,2066,1,4,,46500618,785,Inactive,85666113.0,850333.0,,,Multiplex HTS Screen of TOR pathway GFP-fusion proteins in Saccharomyes cerevisiae_specifically_ AGP1_MLPCN.,Screening,,
313,2094,1,2,,46500618,785,Inactive,67463988.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
314,2094,1,2,,46500618,785,Inactive,67463989.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
315,2094,1,2,,46500618,785,Inactive,166202459.0,,,,Plate Read Microorganism-Based Primary HTS to Identify Modulators of the AI-2 Quorum Sensing System,Screening,,
316,2097,1,2,,46500618,785,Inactive,21361340.0,2932.0,,,Cell-Free Homogeneous Primary HTS to Identify Inhibitors of GSK3beta Activity,Screening,,
317,2098,1,1,,46500618,785,Inactive,62740231.0,15499.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Heat Shock Factor 1 (HSF1).,Screening,,
318,2099,1,1,,46500618,785,Inactive,,,,,Fluorescence Biochemical Primary HTS to Identify Inhibitors of GASC-1 Activity,Screening,,
319,2101,1,1,,17389853,785,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
320,2101,1,1,,26747267,785,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
321,2101,1,1,,50105477,785,Inactive,496369.0,2629.0,,Potency,qHTS Assay for Inhibitors and Activators of N370S glucocerebrosidase as a Potential Chaperone Treatment of Gaucher Disease,Confirmatory,,
322,2107,1,1,,17389853,785,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
323,2107,1,1,,26747267,785,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
324,2107,1,1,,50105477,785,Inactive,757912.0,2717.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Galactosidase From Spleen Homogenate,Confirmatory,,
325,2112,1,1,,17389853,785,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
326,2112,1,1,,26747267,785,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
327,2112,1,1,,50105477,785,Inactive,119393891.0,2548.0,,Potency,qHTS Assay for Inhibitors and Activators of Human alpha-Glucosidase From Spleen Homogenate,Confirmatory,,
328,2120,1,1,,17389853,785,Inactive,32879895.0,3091.0,,Potency,qHTS Assay for Identification of Small Molecule Inducers of Hypoxia Response,Confirmatory,,
329,2129,1,2,,46500618,785,Inactive,510901.0,598.0,,,"Primary biochemical high throughput screening assay to identify inhibitors of BCL2-related protein, long isoform (BCLXL).",Screening,,
330,2130,1,3,,46500618,785,Inactive,7706645.0,51400.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Phosphatase Methylesterase 1 (PME-1).,Screening,,
331,2147,1,1,,26747267,785,Inconclusive,221046486.0,,14.1254,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
332,2147,1,1,,50105477,785,Inactive,221046486.0,,,Potency,qHTS Assay for Inhibitors of  Human Jumonji Domain Containing 2E (JMJD2E),Confirmatory,,
333,2156,2,2,,46500618,785,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ2 potassium channels,Screening,,
334,2174,1,3,,46500618,785,Inactive,5453722.0,10434.0,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 1 (LYPLA1).,Screening,,
335,2177,1,3,,46500618,785,Inactive,4581413.0,,,,Counterscreen for PME1 inhibitors: fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of lysophospholipase 2 (LYPLA2).,Screening,,
336,2216,1,3,,46500618,785,Inactive,,,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the RanGTP-Importin-beta complex,Screening,,
337,2221,1,2,,46500618,785,Inactive,15609874.0,888371.0,,,Fluorescence Cell-Free Homogenous Primary HTS to Identify Inhibitors of RecA Intein Splicing Activity,Screening,,
338,2227,1,2,,46500618,785,Inactive,2935630.0,22066.0,,,Primary cell-based high-throughput screening assay for identification of compounds that allosterically potentiate transient receptor potential cation channel C4 (TRPC4),Screening,,
339,2234,1,2,,46500618,785,Inactive,82503229.0,3783744.0,,,"Counterscreen for inhibitors of EBNA-1: fluorescence polarization-based biochemical high throughput primary assay to identify inhibitors of the Epstein-Barr virus-encoded protein, ZTA.",Screening,,
340,2235,1,2,,46500618,785,Inactive,56790945.0,5499.0,,,Counterscreen for inhibitors of PP5: fluorescence-based biochemical high throughput primary assay to identify inhibitors of Protein Phosphatase 1 (PP1).,Screening,,
341,2237,1,2,,46500618,785,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that activate transient receptor potential cation channel C4 (TRPC4).,Screening,,
342,2239,1,2,,46500618,785,Inactive,18959272.0,170848.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate KCNQ2 potassium channels,Screening,,
343,2247,1,2,,46500618,785,Inactive,2935630.0,22066.0,,,Primary cell-based screen for identification of compounds that inhibit transient receptor potential cation channel C4 (TRPC4).,Screening,,
344,2280,2,3,,46500618,785,Inactive,17507875.0,172532.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of GLD-1 protein - TGE RNA interaction.,Screening,,
345,2300,1,3,,46500618,785,Inactive,216409728.0,10002.0,,,"TR-FRET-based primary biochemical high throughput screening assay to identify agonists of nuclear receptor subfamily 2, group E, member 3 (NR2E3).",Screening,,
346,2323,1,1,,50105477,785,Inactive,254220970.0,,,Potency,qHTS Validation Assay for Identification of Novel General Anesthetics,Confirmatory,,
347,2326,1,1,,50105477,785,Inactive,194352380.0,,,Potency,qHTS Assay for Inhibitors of Influenza NS1 Protein Function,Confirmatory,,
348,2353,1,3,,50105477,785,Inactive,282403581.0,,,Potency,qHTS Validation Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
349,2364,1,2,,50105477,785,Inconclusive,4557365.0,641.0,0.0028,Potency,qHTS Validation Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
350,2391,1,1,,46500618,785,Inactive,,,,IC50,A Cell Based HTS Approach for the Discovery of New Inhibitors of Respiratory syncytial virus (RSV),Confirmatory,,
351,2435,1,2,,46500618,785,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify agonists of the Oxytocin Receptor (OXTR).,Screening,,
352,2445,1,2,,46500618,785,Inactive,32307152.0,5021.0,,,Fluorescence-based primary cell-based high throughput screening assay to identify potentiators of Oxytocin Receptor (OXTR),Screening,,
353,2451,1,2,,26747267,785,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
354,2451,1,2,,50105477,785,Inactive,122920737.0,,,Potency,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia",Confirmatory,,
355,2462,1,1,,46500618,785,Inactive,20336315.0,10018.0,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
356,2462,1,1,,46500618,785,Inactive,167013344.0,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of A1 Apoptosis.,Screening,,
357,2472,1,2,,26747267,785,Inactive,7669492.0,2597.0,,,"qHTS Assay for Inhibitors of Fructose-1,6-bisphosphate Aldolase from Giardia Lamblia: Coupling assay counterscreen",Screening,,
358,2501,1,1,,46500618,785,Active,,,7.46,IC50,"A biochemical assay using the ADP-Hunter methodology, purified TAg, and ATP to identify compounds that inhibit the ATPase activity of Tag - Counter Screen",Confirmatory,,
359,2517,2,1,,17389853,785,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
360,2517,2,1,,26747267,785,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
361,2517,2,1,,50105477,785,Inactive,6980812.0,,,Potency,qHTS Assay for Inhibitors of the Human Apurinic/apyrimidinic Endonuclease 1 (APE1),Confirmatory,,
362,2528,1,2,,17389853,785,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
363,2528,1,2,,26747267,785,Inactive,4557365.0,641.0,,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
364,2528,1,2,,50105477,785,Inconclusive,4557365.0,641.0,0.0028,Potency,qHTS Assay for Inhibitors of Bloom's syndrome helicase (BLM),Confirmatory,,
365,2546,1,1,,17389853,785,Inconclusive,188536040.0,19885.0,35.4813,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
366,2546,1,1,,26747267,785,Inconclusive,188536040.0,19885.0,19.9526,Potency,VP16 counterscreen qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
367,2549,1,1,,17389853,785,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
368,2549,1,1,,26747267,785,Inconclusive,282403581.0,,35.4813,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
369,2549,1,1,,50105477,785,Inactive,282403581.0,,,Potency,qHTS Assay for Inhibitors of RecQ-Like Dna Helicase 1 (RECQ1),Confirmatory,,
370,2550,1,3,,46500618,785,Inactive,160333370.0,22068.0,,,High throughput screening of activators of transient receptor potential cation channel C6 (TRPC6),Screening,,
371,2551,1,1,,17389853,785,Active,188536040.0,19885.0,11.2202,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
372,2551,1,1,,26747267,785,Active,188536040.0,19885.0,11.2202,Potency,qHTS for inhibitors of ROR gamma transcriptional activity,Confirmatory,,
373,2553,1,2,,46500618,785,Inactive,160333370.0,22068.0,,,High throughput screening of inhibitors of transient receptor potential cation channel C6 (TRPC6),Screening,,
374,2557,1,3,,46500618,785,Inactive,67191027.0,3676.0,,,HTS for Identification of VLA-4 Allosteric Modulators from MLPCN library,Screening,,
375,2563,1,1,,46500618,785,Inactive,6323930.0,855317.0,,,Fluorescence Cell-Free Homogenous Primary HTS  to Identify Inhibitors of the Ras-converting Enzyme,Screening,,
376,2606,1,2,,46500618,785,Inactive,15610807.0,885176.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the membrane-associated serine protease Rv3671c in M.tuberculosis,Screening,,
377,2629,1,1,,46500618,785,Inactive,139472804.0,4961527.0,,,Fluorescence Polarization Cell-Free Homogeneous Primary HTS to Identify Inhibitors of the LANA Histone H2A/H2B Interaction,Screening,,
378,2642,1,2,,46500618,785,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit KCNQ1 potassium channels,Screening,,
379,2648,1,2,,46500618,785,Inactive,32479527.0,3784.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate KCNQ1 potassium channels,Screening,,
380,2650,2,1,,46500618,785,Inactive,49574532.0,2931.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of GSK-3 alpha,Screening,,
381,2660,1,1,,90340863,785,Inconclusive,4826730.0,2475.0,23.2809,Potency,"Cytometric Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
382,2661,1,1,,46500618,785,Inactive,23943882.0,65975.0,,,Luminescence Cell-Free  Homogenous Primary HTS to Identify Inhibitors of Serine/Threonine  Kinase 33  Activity,Screening,,
383,2662,2,1,,85231080,785,Inactive,56550039.0,4297.0,,Potency,qHTS Fluorescence Polarization Assay for Inhibitors of MLL CXXC domain - DNA interaction,Confirmatory,,
384,2666,1,1,,90340863,785,Inconclusive,4826730.0,2475.0,14.6892,Potency,"High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF (Tsc2-/-, p53-/-) Cells",Confirmatory,,
385,2667,1,1,,90340863,785,Inactive,4826730.0,2475.0,,Potency,High Content Imaging Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF Cells,Confirmatory,,
386,2668,1,1,,90340863,785,Inconclusive,4826730.0,2475.0,14.6892,Potency,Cytometry Cell-Based qHTS for Inhibitors of the mTORC1 Signaling Pathway in MEF cells,Confirmatory,,
387,2675,1,1,,50105477,785,Unspecified,41281591.0,4154.0,,Potency,qHTS Assay for Inhibitors of MBNL1-poly(CUG) RNA binding,Confirmatory,,
388,2690,1,2,,46500618,785,Inactive,,,,,A yeast HTS for caloric restriction mimetics that inhibit age-related superoxide,Screening,,
389,2716,1,1,,46500618,785,Inactive,,,,,Luminescence  Microorganism Primary HTS to Identify Inhibitors of the SUMOylation Pathway Using a Temperature Sensitive Growth Reversal Mutant Mot1-301,Screening,,
390,2717,1,2,,46500618,785,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Cancer Stem Cells,Screening,,
391,2718,1,1,,46500618,785,Inactive,13128862.0,8841.0,,,Fluorescence Cell-Free Homogeneous Primary HTS to Identify Inhibitors of Histone Deacetylase 3,Screening,,
392,2732,1,1,,17405139,785,Inactive,160707929.0,13198.0,,,HTS for small molecule inhibitors of CHOP to regulate the unfolded protein response to ER stress,Screening,,
393,2751,2,2,,46500618,785,Inactive,153217451.0,9581.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the prolyl oligopeptidase-like enzyme (PREPL),Screening,,
394,2774,1,3,,92304032,785,Inactive,,,,,LOPAC Circadian Assay,Screening,,
395,2796,1,4,,46500618,785,Inactive,4502003.0,196.0,,,Luminescence-based primary cell-based high throughput screening assay to identify activators of the Aryl Hydrocarbon Receptor (AHR),Screening,,
396,2797,1,2,,46500618,785,Inactive,4502331.0,552.0,,,Counterscreen for Oxytocin Receptor (OXTR) agonists: Fluorescence-based primary cell-based high throughput assay to identify agonists of the vasopressin 1 receptor (V1R),Screening,,
397,23251,3,3,,103176079,785,Unspecified,,,,,Partition coefficient (logP),Other,3599019.0,
398,23252,3,3,,103176079,785,Unspecified,,,,,Partition coefficient (logP) (benzene),Other,3599019.0,
399,23253,3,3,,103176079,785,Unspecified,,,,,Partition coefficient (logP) (carbon tetrachloride),Other,3599019.0,
400,23254,3,3,,103176079,785,Unspecified,,,,,Partition coefficient (logP) (chloroform),Other,3599019.0,
401,23255,3,3,,103176079,785,Unspecified,,,,,Partition coefficient (logP) (ether),Other,3599019.0,
402,23256,3,3,,103176079,785,Unspecified,,,,,Partition coefficient (logP) (hexane),Other,3599019.0,
403,282833,4,4,,103176079,785,Unspecified,,,,,Activity against caspase-mediated apoptosis in mouse L1210 cells at 0.1 mM,Other,16279782.0,
404,282835,6,2,,103176079,785,Unspecified,,,,IC50,Cytotoxicity against mouse L1210 cells,Confirmatory,16279782.0,
405,288184,9,1,,103176079,785,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of unstirred water layer by PAMPA,Other,17418579.0,
406,288185,7,1,,103176079,785,Unspecified,,,,,Permeability coefficient through artificial membrane in presence of stirred water layer,Other,17418579.0,
407,288191,3,4,,103176079,785,Unspecified,,,,,Membrane retention in permeability experiment with artificial membrane,Other,17418579.0,
408,288192,3,4,,103176079,785,Unspecified,,,,,"Partition coefficient, log P of the compound",Other,17418579.0,
409,305160,9,5,,103176079,785,Active,6686057.0,,33.48,IC50,Inhibition of mushroom tyrosinase,Confirmatory,17064896.0,
410,309363,3,3,,103176079,785,Unspecified,,,,,Antiinflammatory activity in CD1 mouse assessed as inhibition of croton oil-induced ear oedema at 0.3 umol/cm^2 after 6 hrs,Other,17768049.0,
411,331282,9,5,,103176079,785,Active,6686057.0,,37.0,IC50,Inhibition of mushroom tyrosinase,Confirmatory,18501598.0,
412,331291,9,5,,103176079,785,Active,115449.0,759.0,10.7,Ki,Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydrase assay,Confirmatory,18501600.0,
413,331292,9,5,,103176079,785,Active,115456.0,760.0,0.09,Ki,Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydrase assay,Confirmatory,18501600.0,
414,331293,9,5,,103176079,785,Active,30580362.0,80733.0,10.6,Ki,Inhibition of mouse recombinant carbonic anhydrase 15 by stopped-flow CO2 hydrase assay,Confirmatory,18501600.0,
415,336442,9,2,,103176079,785,Unspecified,6686057.0,,4500.0,IC50,Inhibition of mushroom tyrosinase,Confirmatory,12398542.0,
416,336478,3,7,,103176079,785,Unspecified,,,,,Inhibition of COX2 at 100 uM by scintillation proximity assay,Other,12444669.0,
417,338268,7,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis DSM 347 after 18 hrs by twofold serial dilution method,Other,7714539.0,
418,338269,7,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Micrococcus luteus DSM 348 after 18 hrs by twofold serial dilution method,Other,7714539.0,
419,338270,7,3,,103176079,785,Inactive,,,,,Antimicrobial activity against Candida albicans DSM 1665 after 18 hrs by twofold serial dilution method,Other,7714539.0,
420,338271,3,5,,103176079,785,Inactive,,,,,Antimicrobial activity against Escherichia coli DSM 1103 after 18 hrs by twofold serial dilution method,Other,7714539.0,
421,338272,3,5,,103176079,785,Inactive,,,,,Antimicrobial activity against Pseudomonas aeruginosa DSM 1117 after 18 hrs by twofold serial dilution method,Other,7714539.0,
422,338273,6,3,,103176079,785,Unspecified,,,,,Toxicity against Artemia salina after 24 hrs,Other,7714539.0,
423,338274,6,3,,103176079,785,Unspecified,,,,,Toxicity against Gambusia affinis,Other,7714539.0,
424,342475,9,5,,103176079,785,Active,115449.0,759.0,10.7,Ki,Inhibition of human carbonic anhydrase 1 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
425,342476,9,5,,103176079,785,Active,115456.0,760.0,0.09,Ki,Inhibition of human carbonic anhydrase 2 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
426,342477,9,5,,103176079,785,Active,134047703.0,761.0,8.2,Ki,Inhibition of human carbonic anhydrase 3 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
427,342478,9,5,,103176079,785,Active,115465.0,762.0,10.8,Ki,Inhibition of human carbonic anhydrase 4 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
428,342479,9,5,,103176079,785,Active,461680.0,763.0,14.1,Ki,Inhibition of human carbonic anhydrase 5A by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
429,342480,9,5,,103176079,785,Active,8928041.0,11238.0,12.5,Ki,Inhibition of human carbonic anhydrase 5B by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
430,342481,9,5,,103176079,785,Unspecified,116241278.0,765.0,521.0,Ki,Inhibition of human carbonic anhydrase 6 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
431,342482,9,5,,103176079,785,Unspecified,1168744.0,766.0,883.0,Ki,Inhibition of human carbonic anhydrase 7 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
432,342483,9,5,,103176079,785,Active,83300925.0,768.0,32.5,Ki,Inhibition of human carbonic anhydrase 9 catalytic domain by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
433,342484,9,5,,103176079,785,Active,5915866.0,771.0,7.8,Ki,Inhibition of human carbonic anhydrase 12 catalytic domain by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
434,342485,9,5,,103176079,785,Active,8928036.0,23632.0,42.0,Ki,Inhibition of human carbonic anhydrase 14 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
435,342486,9,5,,103176079,785,Unspecified,30580372.0,71934.0,74.3,Ki,Inhibition of mouse carbonic anhydrase 13 by stopped-flow CO2 hydration assay,Confirmatory,18579385.0,
436,346025,3,3,,103176079,785,Unspecified,,,,,Binding affinity to beta cyclodextrin,Other,19056282.0,
437,349291,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 250 ug/ml after 4 hrs by XTT assay relative to control,Other,18093697.0,
438,349292,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 125 ug/ml after 4 hrs by XTT assay relative to control,Other,18093697.0,
439,349293,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 62.5 ug/ml after 4 hrs by XTT assay relative to control,Other,18093697.0,
440,349294,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 31.2 ug/ml after 4 hrs by XTT assay relative to control,Other,18093697.0,
441,349295,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 15.6 ug/ml after 4 hrs by XTT assay relative to control,Other,18093697.0,
442,349296,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 7.8 ug/ml after 4 hrs by XTT assay relative to control,Other,18093697.0,
443,349297,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as bacterial growth at 3.9 ug/ml after 4 hrs by XTT assay relative to control,Other,18093697.0,
444,349300,7,1,,103176079,785,Unspecified,,,,,Antimicrobial activity against Streptococcus mutans ATCC 25175 assessed as inhibition of biofilm formation at 31.3 ug/ml after 48 hrs,Other,18093697.0,
445,349301,3,3,,103176079,785,Inactive,,,,,Antimicrobial activity against Streptococcus mutans ATCC 25175 assessed as effect on bacterial growth after 4 hrs by XTT assay relative to control,Other,18093697.0,
446,349303,4,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Porphyromonas gingivalis ATCC 33277 assessed as reduction of biofilm formation at 3.9 ug/ml after 48 hrs,Other,18093697.0,
447,395015,9,5,,103176079,785,Active,6686057.0,,9.81,IC50,Inhibition of mushroom tyrosinase activity after 20 mins,Confirmatory,19181523.0,
448,395016,6,3,,103176079,785,Active,,,3.97,IC50,Inhibition of melanin formation in C57BL/6J mouse Melan-a cells,Confirmatory,19181523.0,
449,395021,3,5,,103176079,785,Unspecified,,,,,Cytotoxicity against C57BL/6J mouse Melan-a cells assessed as cell survival at 10 uM by modified crystal violet assay,Other,19181523.0,
450,398960,5,1,,103176079,785,Unspecified,,,,,Cytotoxicity against human KB cells,Other,6736973.0,
451,398961,5,1,,103176079,785,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,6736973.0,
452,400520,9,2,,103176079,785,Unspecified,6686057.0,,4500.0,IC50,Inhibition of mushroom tyrosinase by spectrophotometry,Confirmatory,15043425.0,
453,403614,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis at 120 ug/disk,Other,9214736.0,
454,403615,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis at 60 ug/disk,Other,9214736.0,
455,403616,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Bacillus subtilis at 30 ug/disk,Other,9214736.0,
456,403618,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Escherichia coli at 120 ug/disk,Other,9214736.0,
457,403619,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Escherichia coli at 60 ug/disk,Other,9214736.0,
458,403620,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Escherichia coli at 30 ug/disk,Other,9214736.0,
459,403622,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa at 120 ug/disk,Other,9214736.0,
460,403623,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa at 60 ug/disk,Other,9214736.0,
461,403624,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Pseudomonas aeruginosa at 30 ug/disk,Other,9214736.0,
462,403626,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Trichophyton mentagrophytes at 120 ug/disk,Other,9214736.0,
463,403899,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Trichophyton mentagrophytes at 60 ug/disk,Other,9214736.0,
464,403900,3,3,,103176079,785,Unspecified,,,,,Antimicrobial activity against Trichophyton mentagrophytes at 30 ug/disk,Other,9214736.0,
465,403902,3,4,,103176079,785,Unspecified,,,,,Cytotoxicity against african green monkey BSC1 cells at 120 ug/disk,Other,9214736.0,
466,403903,3,4,,103176079,785,Unspecified,,,,,Cytotoxicity against african green monkey BSC1 cells at 60 ug/disk,Other,9214736.0,
467,403904,3,4,,103176079,785,Unspecified,,,,,Cytotoxicity against african green monkey BSC1 cells at 30 ug/disk,Other,9214736.0,
468,403906,6,2,,103176079,785,Unspecified,,,,,Cytotoxicity against mouse P388 cells,Other,9214736.0,
469,405958,7,6,,103176079,785,Unspecified,6686057.0,,4500.0,IC50,Inhibition of mushroom tyrosinase activity after 10 mins,Confirmatory,18505286.0,
470,421667,6,2,,103176079,785,Active,,,2.2,IC50,Inhibition of melanin synthesis in NHEM cells assessed as [14C]thiouracil incorporation after 72 hrs by liquid scintillation counting,Confirmatory,19132934.0,
471,422532,6,2,,103176079,785,Unspecified,,,103.0,IC50,Inhibition of melanin synthesis in NHEM after 24 hrs by liquid scintillation,Confirmatory,19102656.0,
472,434955,1,2,,46500618,785,Inactive,,,,IC90,Screen to Identify Novel Compounds That Sensitize Mycobacterium Tuberculosis to Beta-lactam Antibiotics,Confirmatory,,
473,434962,1,2,,46500618,785,Inactive,155969707.0,3416.0,,,Fluorescence polarization-based cell-based primary high throughput screening assay to identify inhibitors of insulin-degrading enzyme (IDE),Screening,,
474,434989,1,1,,46500618,785,Inactive,222080095.0,3061.0,,,Fluorescence-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
475,435005,1,1,,46500618,785,Inactive,,,,,Luminescence Cell-Based Primary HTS to Identify Inhibitors of Beta Cell Apoptosis.,Screening,,
476,435030,1,2,,46500618,785,Inactive,15645703.0,899625.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
477,435030,1,2,,46500618,785,Inactive,15646160.0,899738.0,,,Absorbance-based primary bacterial cell-based high throughput screening assay to identify inhibitors of AddAB recombination protein complex,Screening,,
478,449728,1,2,,46500618,785,Inactive,,,,,Counterscreen for inhibitors of AddAB: absorbance-based bacterial cell-based high throughput screening assay to identify inhibitors of bacterial viability,Screening,,
479,449739,1,2,,46500618,785,Inactive,53832009.0,8912.0,,,Inhibitors of Cav3 T-type Calcium Channels: Primary Screen,Screening,,
480,449762,1,2,,46500618,785,Inactive,,,,IC50,High Throughput Screening Assay used to Identify Novel Compounds that Inhibit Mycobacterium Tuberculosis in 7H9 Media,Confirmatory,,
481,449768,1,1,,46500618,785,Inactive,7108463.0,6531.0,,,High Throughput Screening for Cocaine Antagonists: Primary Screen,Screening,,
482,463079,1,2,,46500618,785,Inactive,,,,,Fluorescence-based counterscreen for orexin 1 receptor (OX1R) antagonists: cell-based assay to identify antagonists of the parental CHO cell line,Screening,,
483,463082,1,1,,46500618,785,Inactive,270133071.0,7941.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of the plasma platelet activating factor acetylhydrolase (pPAFAH),Screening,,
484,463096,1,1,,50105477,785,Inconclusive,,,11.2202,Potency,Validation screen for inhibitors of Lassa infection,Confirmatory,,
485,463097,1,1,,50105477,785,Inconclusive,7705682.0,51053.0,25.1189,Potency,Validation screen for small molecules that induce DNA re-replication in MCF 10A normal breast cells,Confirmatory,,
486,463106,1,2,,90340863,785,Inactive,188528692.0,9099.0,,Potency,qHTS Validation Assay for Inhibitors of Ubiquitin-specific Protease USP2a Using CHOP2 as the Reporter,Confirmatory,,
487,463111,1,1,,46500618,785,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that potentiate/activate regulator of G-protein signaling 4 (RGS4),Screening,,
488,463141,1,2,,46500618,785,Inactive,14790119.0,836.0,,,Absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-3,Screening,,
489,463165,1,1,,46500618,785,Inactive,5032039.0,5999.0,,,Primary cell-based high-throughput screening assay for identification of compounds that inhibit regulator of   G-protein signaling 4 (RGS4),Screening,,
490,463189,1,1,,53777683,785,Inactive,,,,,96-well format Chlamydomonas reinhardtii Algae Gravitaxis Assay to measure the difference in the absorbance between the small compact plug of WT swimming algae versus the MUT algae lacking cilia.,Screening,,
491,463210,1,2,,46500618,785,Inactive,55960760.0,,,,Counterscreen for procaspase-3 activators: absorbance-based primary biochemical high throughput screening assay to identify activators of procaspase-7,Screening,,
492,467606,6,6,,103176079,785,Unspecified,6686057.0,,4210.0,IC50,Inhibition of mushroom tyrosinase after 10 mins by spectrophotometry,Confirmatory,19555125.0,
493,478727,3,3,,103176079,785,Active,,,,,Reduction of pigmentation in UV-induced hyperpigmentation brown guinea pig model at 2% applied topically bid for 4 weeks,Other,20149498.0,
494,485270,1,1,,46500618,785,Inactive,222080095.0,3061.0,,,FRET-based cell-based primary high throughput screening assay to identify antagonists of the orexin 1 receptor (OX1R; HCRTR1),Screening,,
495,485272,1,1,,46500618,785,Inactive,216548487.0,23569.0,,,Fluorescence polarization-based primary biochemical high throughput screening assay to identify inhibitors of Protein Arginine Deiminase 4 (PAD4) (1536 HTS),Screening,,
496,485275,1,3,,46500618,785,Inactive,,,,,Phenotypic HTS multiplex for antifungal efflux pump inhibitors,Screening,,
497,485290,1,1,,17389853,785,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
498,485290,1,1,,26747267,785,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
499,485290,1,1,,50105477,785,Inactive,20150581.0,,,Potency,qHTS Assay for Inhibitors of Tyrosyl-DNA Phosphodiesterase (TDP1),Confirmatory,,
500,485295,1,2,,90340863,785,Active,30027657.0,,5.3233,Potency,qHTS Validation Assay for the Inhibitors of DNA Replication in Gram-Positive Bacteria,Confirmatory,,
501,485297,1,1,,90340863,785,Inactive,4759012.0,9367.0,58.0479,Potency,qHTS Assay for Rab9 Promoter Activators,Confirmatory,,
502,485298,1,1,,90340863,785,Inactive,,,,Potency,qHTS Assay for Small Molecule Inhibitors of Mitochondrial Division or Activators of Mitochondrial Fusion,Confirmatory,,
503,485313,1,2,,90340863,785,Inactive,255652944.0,4864.0,91.9997,Potency,qHTS Assay for NPC1 Promoter Activators,Confirmatory,,
504,485314,1,1,,50105477,785,Inactive,4505931.0,5423.0,,Potency,qHTS Assay for Inhibitors of DNA Polymerase Beta,Confirmatory,,
505,485342,1,2,,90340863,785,Inactive,5454140.0,7251.0,,Potency,qHTS Validation Assay for Iinhibitors of HIV-1 Budding by Blocking the Interaction of PTAP/TSG101,Confirmatory,,
506,485345,1,2,,90340863,785,Inactive,,,,Potency,qHTS Validation Assay to Find Inhibitors of Chronic Active B-Cell Receptor Signaling,Confirmatory,,
507,485350,1,2,,92124719,785,Inactive,126642418.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme BasE,Screening,,
508,485366,1,2,,90340863,785,Inactive,4501969.0,154.0,,Potency,qHTS validation assay of beta-arrestin-biased ligands of beta2-adrenergic receptor,Confirmatory,,
509,485368,1,2,,90340863,785,Active,72386991.0,3656265.0,10.690999999999999,Potency,qHTS Validation Assay to Find Inhibitors of T. brucei phosphofructokinase,Confirmatory,,
510,488745,1,4,,85231080,785,Active,,,10.4179,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
511,488752,1,4,,85231080,785,Active,,,8.2753,Potency,"Quantitative high throughput screen for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
512,488772,1,1,,90340863,785,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
513,488773,1,2,,90340863,785,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1),Confirmatory,,
514,488816,1,1,,90340863,785,Inactive,4758356.0,2237.0,,Potency,qHTS Validation Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1),Confirmatory,,
515,488837,1,1,,90340863,785,Inactive,26667227.0,2139.0,,Potency,qHTS Assay for Inhibitors of the Phosphatase Activity of Eya2,Confirmatory,,
516,488847,1,3,,46500618,785,Inactive,148539876.0,156.0,,,RNA aptamer-based HTS for inhibitors of GRK2,Screening,,
517,488890,1,2,,46500618,785,Inactive,,,,IC50,"Elucidation of physiology of non-replicating, drug-tolerant Mycobacterium tuberculosis",Confirmatory,,
518,488922,1,2,,46500618,785,Inactive,7706135.0,,,,Primary cell-based screen for identification of compounds that inhibit the two-pore domain potassium channel KCNK9,Screening,,
519,488949,1,2,,85231080,785,Inconclusive,41055989.0,54737.0,89.1251,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
520,488949,1,2,,90340863,785,Inactive,41055989.0,54737.0,,Potency,qHTS Validation Assay for Inhibitors for MPP8 Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
521,488953,1,1,,90340863,785,Inconclusive,187960037.0,10951.0,56.2341,Potency,qHTS Validation Assay for Inhibitors of HP1-beta Chromodomain Interactions with Methylated Histone Tails,Confirmatory,,
522,488975,1,2,,46500618,785,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that inhibit the Choline Transporter (CHT),Screening,,
523,488977,1,2,,46500618,785,Inactive,11141885.0,60482.0,,,Primary cell-based screen for identification of compounds that allosterically activate the Choline Transporter (CHT),Screening,,
524,488978,1,1,,90340863,785,Inactive,45359078.0,,,Potency,High-Throughput Screening for Modulators of Cytosolic Chaperonin Activity: MmCpn Primary Screen,Confirmatory,,
525,488979,1,1,,50105477,785,Inactive,74315350.0,7442.0,,Potency,HTS Assay for Compounds that Act as Enhancers of the Vanilloid Receptor 1,Confirmatory,,
526,488980,1,1,,85231080,785,Inactive,38016895.0,7253.0,,Potency,qHTS Assay for Antagonists of the Thyroid Stimulating Hormone Receptor,Confirmatory,,
527,488981,1,1,,90340863,785,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Agonists,Confirmatory,,
528,488982,1,1,,90340863,785,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Potentiators,Confirmatory,,
529,488983,1,1,,90340863,785,Inactive,4503383.0,1812.0,,Potency,HTS Assay for Allosteric Agonists of the Human D1 Dopamine Receptor: Primary Screen for Antagonists,Confirmatory,,
530,493033,1,2,,92124719,785,Active,614089026.0,,,,A screen for compounds that inhibit the bacterial siderophore biosynthetic enzyme MbtI,Other,,
531,493106,1,1,,90340863,785,Inactive,116283940.0,79915.0,,Potency,Validation screen for small molecules that induce genotoxicity in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
532,493107,1,1,,90340863,785,Inconclusive,116283940.0,79915.0,20.5878,Potency,Validation screen for small molecules that inhibit ELG1-dependent DNA repair in human embryonic kidney (HEK293T) cells expressing luciferase-tagged ELG1,Confirmatory,,
533,493127,1,1,,50105477,785,Inactive,4507681.0,7201.0,,,qHTS for Small Molecule Agonists and Allosteric Enhancers of Human TRH Receptor: Validation Screen for Agonists,Screening,,
534,493153,1,1,,90340863,785,Inactive,,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
535,493153,1,1,,90340863,785,Inactive,224028257.0,4780.0,,Potency,Nrf2 qHTS screen for inhibitors: Validation,Confirmatory,,
536,493164,1,2,,90340863,785,Inactive,6679377.0,18792.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
537,493164,1,2,,90340863,785,Inactive,7242179.0,18793.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
538,493164,1,2,,90340863,785,Inactive,257471003.0,18815.0,,Potency,qHTS for Inhibitors of Cell Surface uPA Generation: Validation Assay,Confirmatory,,
539,493189,1,1,,50105477,785,Inactive,4503895.0,2584.0,,Potency,qHTS Validation Assay for Inhibitors of Human Galactokinase (GALK),Confirmatory,,
540,493982,7,5,,103176079,785,Active,6686057.0,,33.48,IC50,Inhibition of mushroom tyrosinase,Confirmatory,20619644.0,
541,497310,6,1,,103176079,785,Unspecified,,,75.0,IC50,Inhibition of tyrosinase,Confirmatory,20615711.0,
542,504327,1,1,,90340863,785,Inactive,153791535.0,2648.0,,Potency,qHTS Assay for Inhibitors of GCN5L2,Confirmatory,,
543,504332,1,1,,50105477,785,Active,168985070.0,,1.7783,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
544,504332,1,1,,90340863,785,Active,168985070.0,,5.9728,Potency,qHTS Assay for Inhibitors of Histone Lysine Methyltransferase G9a,Confirmatory,,
545,504364,1,1,,85231080,785,Inactive,7705682.0,51053.0,,Potency,Validation screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells,Confirmatory,,
546,504406,1,1,,46500618,785,Inactive,15610945.0,886142.0,,,Inhibitors of Mycobacterium tuberculosis UDP-galactopyranose mutase (UGM) enzyme - High throughput screening using Fluorescent polarization assay Measured in Biochemical System Using Plate Reader - 2105-01_Inhibitor_SinglePoint_HTS_Activity_Set6,Screening,,
547,504408,2,1,,46500618,785,Inactive,,,,,Heat Shock Factor-1 (HSF-1) Measured in Cell-Based System Using Plate Reader - 2038-01_Activator_SinglePoint_HTS_Activity,Screening,,
548,504536,1,1,,90340863,785,Inconclusive,5453898.0,5300.0,8.4921,Potency,qHTS Validation Assay to Find Inhibitors of Pin1,Confirmatory,,
549,504547,1,1,,90340863,785,Inactive,115503961.0,4357161.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Kinase,Confirmatory,,
550,504548,1,2,,90340863,785,Inactive,157877932.0,5655980.0,,Potency,qHTS Validation Assay to Find Inhibitors of Phosphoglycerate Mutase,Confirmatory,,
551,504749,1,3,,17389853,785,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
552,504749,1,3,,104171174,785,Unspecified,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
553,504749,1,3,1.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
554,504749,1,3,2.0,104171174,785,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
555,504749,1,3,3.0,104171174,785,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
556,504749,1,3,4.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
557,504749,1,3,5.0,104171174,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
558,504749,1,3,6.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
559,504749,1,3,7.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
560,504749,1,3,8.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
561,504749,1,3,9.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
562,504749,1,3,10.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
563,504749,1,3,11.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
564,504749,1,3,12.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
565,504749,1,3,13.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
566,504749,1,3,14.0,104171174,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
567,504749,1,3,15.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
568,504749,1,3,16.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
569,504749,1,3,17.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
570,504749,1,3,18.0,17389853,785,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
571,504749,1,3,19.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
572,504749,1,3,20.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
573,504749,1,3,21.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
574,504749,1,3,22.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
575,504749,1,3,23.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
576,504749,1,3,24.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
577,504749,1,3,25.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
578,504749,1,3,26.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
579,504749,1,3,27.0,104171174,785,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
580,504749,1,3,28.0,104171174,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
581,504749,1,3,29.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
582,504749,1,3,30.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
583,504749,1,3,31.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
584,504749,1,3,32.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
585,504749,1,3,33.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
586,504749,1,3,34.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
587,504749,1,3,35.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
588,504749,1,3,36.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
589,504749,1,3,37.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
590,504749,1,3,38.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
591,504749,1,3,39.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
592,504749,1,3,40.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
593,504749,1,3,41.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
594,504749,1,3,42.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
595,504749,1,3,43.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
596,504749,1,3,44.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
597,504749,1,3,45.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
598,504749,1,3,46.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
599,504749,1,3,47.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
600,504749,1,3,48.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
601,504749,1,3,49.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
602,504749,1,3,50.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
603,504749,1,3,51.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
604,504749,1,3,52.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
605,504749,1,3,53.0,104171174,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
606,504749,1,3,54.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
607,504749,1,3,55.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
608,504749,1,3,56.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
609,504749,1,3,57.0,17389853,785,Active,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
610,504749,1,3,58.0,17389853,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
611,504749,1,3,59.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
612,504749,1,3,60.0,104171174,785,Inconclusive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
613,504749,1,3,61.0,17389853,785,Inactive,,,,,qHTS profiling for inhibitors of Plasmodium falciparum proliferation,Other,21817045.0,
614,504770,1,2,,92124719,785,Inactive,9657380.0,2612528.0,,,A screen for compounds that inhibit replication of Vibrio cholerae chromosome II,Other,,
615,504810,1,2,,90340863,785,Inactive,118341367.0,7253.0,,,Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
616,504812,1,2,,90340863,785,Inactive,118341367.0,7253.0,,,Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign,Screening,20427476.0,
617,504821,1,1,,85231080,785,Inactive,38016895.0,7253.0,,Potency,Antagonists of the Thyroid Stimulating Hormone Receptor: Validation,Confirmatory,,
618,504832,1,1,,104171174,785,Inactive,,,,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 48 hour incubation",Confirmatory,,
619,504834,1,1,,104171174,785,Inconclusive,,,8.4921,Potency,"Primary qHTS for delayed death inhibitors of the malarial parasite plastid, 96 hour incubation",Confirmatory,,
620,504836,1,2,,90340863,785,Inactive,168984549.0,,,Potency,Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in human glioma: Validation,Confirmatory,11836247.0,
621,504845,1,1,,90340863,785,Inconclusive,86301163.0,5999.0,23.7781,Potency,Inhibitors of Regulator of G Protein Signaling (RGS) 4: qHTS,Confirmatory,,
622,504847,1,1,,90340863,785,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
623,504847,1,1,,104171174,785,Inactive,63054845.0,7421.0,,Potency,Inhibitors of the vitamin D receptor (VDR): qHTS,Confirmatory,,
624,504865,1,1,,90340863,785,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
625,504865,1,1,,104171174,785,Inactive,118600387.0,7398.0,,Potency,Inhibitors of USP1/UAF1: Pilot qHTS,Confirmatory,,
626,521220,3,3,,103176079,785,Inactive,,,,,Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay,Other,17417631.0,
627,524790,7,2,,103176079,785,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum 3D7 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
628,524793,7,2,,103176079,785,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum Dd2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
629,524794,7,1,,103176079,785,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum GB4 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
630,524795,7,2,,103176079,785,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum HB3 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
631,524796,7,1,,103176079,785,Active,,,12.5893,IC50,Antiplasmodial activity against Plasmodium falciparum W2 after 72 hrs by SYBR green assay,Confirmatory,19734910.0,
632,540256,1,2,,50105477,785,Inconclusive,,,11.2202,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
633,540256,1,2,,90340863,785,Inconclusive,,,32.6294,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
634,540276,1,2,,11111286,785,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
635,540276,1,2,,17389853,785,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
636,540276,1,2,,26747267,785,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
637,540276,1,2,,26747268,785,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
638,540276,1,2,,50105477,785,Active,420597.0,,7.9433,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
639,540276,1,2,,50105478,785,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
640,540276,1,2,,85231080,785,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
641,540276,1,2,,90340863,785,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
642,540276,1,2,,104171174,785,Inactive,420597.0,,,Potency,qHTS for inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
643,540299,1,2,,92124719,785,Inactive,15607688.0,887529.0,,,A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis,Other,20850304.0,
644,588211,2,3,,103176079,785,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in humans",Other,20014752.0,
645,588212,2,3,,103176079,785,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in rodents",Other,20014752.0,
646,588213,2,3,,103176079,785,Unspecified,,,,,"Literature-mined compound from Fourches et al multi-species drug-induced liver injury (DILI) dataset, effect in non-rodents",Other,20014752.0,
647,588349,1,1,,90340863,785,Inconclusive,,,39.8107,Potency,qHTS for Inhibitors of ATXN expression: Validation of Cytotoxic Assay,Confirmatory,,
648,588378,1,1,,90340863,785,Inconclusive,171543895.0,6311.0,39.8107,Potency,qHTS for Inhibitors of ATXN expression: Validation,Confirmatory,,
649,588453,1,1,,85231080,785,Inconclusive,8659577.0,58819.0,56.2341,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
650,588453,1,1,,90340863,785,Inconclusive,8659577.0,58819.0,9.4662,Potency,qHTS Assay for Inhibitors of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
651,588456,1,1,,90340863,785,Inactive,8659577.0,58819.0,,Potency,qHTS Assay for Substrates of Mammalian Selenoprotein Thioredoxin Reductase 1 (TrxR1): qHTS,Confirmatory,,
652,588511,1,2,,46500618,785,Inactive,334278898.0,101772.0,,,Primary cell-based high-throughput screening for identification of compounds that inhibit/block calcium-activated chloride channels (TMEM16A),Screening,,
653,588513,1,1,,17389853,785,Inconclusive,348019627.0,2099.0,50.1187,Potency,qHTS assay for small molecule antagonists of estrogen receptor alpha signaling,Confirmatory,,
654,588514,1,1,,17389853,785,Inconclusive,348019627.0,2099.0,35.4813,Potency,qHTS assay for small molecule agonists of estrogen receptor alpha signaling,Confirmatory,,
655,588515,1,1,,17389853,785,Inactive,124375976.0,367.0,,Potency,qHTS assay for small molecule agonists of androgen receptor signaling,Confirmatory,,
656,588516,1,1,,17389853,785,Inconclusive,124375976.0,367.0,44.6684,Potency,qHTS assay for small molecule antagonists of androgen receptor signaling,Confirmatory,,
657,588519,1,2,,92124719,785,Inactive,52695378.0,,,,A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities,Other,21722674.0,
658,588526,1,1,,17389853,785,Inconclusive,325495553.0,9971.0,14.1254,Potency,qHTS assay for small molecule antagonists of farnesoid X receptor signaling,Confirmatory,,
659,588527,1,1,,17389853,785,Inconclusive,325495553.0,9971.0,44.6684,Potency,qHTS assay for small molecule agonists of farnesoid X receptor signaling,Confirmatory,,
660,588532,1,1,,17389853,785,Inactive,311348376.0,2908.0,,Potency,qHTS assay for small molecule agonists of glucocorticoid receptor signaling,Confirmatory,,
661,588533,1,1,,17389853,785,Inconclusive,311348376.0,2908.0,14.1254,Potency,qHTS assay for small molecule antagonists of glucocorticoid receptor signaling,Confirmatory,,
662,588534,1,1,,17389853,785,Inconclusive,216409690.0,5467.0,22.3872,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
663,588535,1,1,,17389853,785,Inconclusive,216409690.0,5467.0,25.1189,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor delta signaling,Confirmatory,,
664,588536,1,1,,17389853,785,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule agonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
665,588537,1,1,,17389853,785,Inconclusive,216409692.0,5468.0,,Potency,qHTS assay for small molecule antagonists of peroxisome proliferator-activated receptor gamma signaling,Confirmatory,,
666,588541,1,1,,17389853,785,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule antagonists of vitamin D receptor signaling,Confirmatory,,
667,588543,1,1,,17389853,785,Inconclusive,216409708.0,7421.0,,Potency,qHTS assay for small molecule agonists of vitamin D receptor signaling,Confirmatory,,
668,588544,1,1,,17389853,785,Inconclusive,325495497.0,6256.0,11.2202,Potency,qHTS assay for small molecule agonists of retinoid X receptor alpha signaling,Confirmatory,,
669,588545,1,1,,17389853,785,Inactive,189491771.0,7068.0,,Potency,qHTS assay for small molecule agonists of thyroid hormone receptor beta signaling,Confirmatory,,
670,588546,1,1,,17389853,785,Inconclusive,325495497.0,6256.0,8.9125,Potency,qHTS assay for small molecule antagonists of retinoid X receptor alpha signaling,Confirmatory,,
671,588547,1,1,,17389853,785,Inconclusive,189491771.0,7068.0,39.8107,Potency,qHTS assay for small molecule antagonists of thyroid hormone receptor beta signaling,Confirmatory,,
672,588579,1,1,,90340863,785,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
673,588579,1,1,,104171174,785,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
674,588579,1,1,,124880354,785,Inactive,7705344.0,51426.0,,Potency,qHTS for Inhibitors of Polymerase Kappa,Confirmatory,,
675,588590,1,1,,50105477,785,Inactive,154350220.0,11201.0,,Potency,qHTS for Inhibitors of Polymerase Iota,Confirmatory,,
676,588591,1,1,,50105477,785,Inactive,5729982.0,5429.0,,Potency,qHTS for Inhibitors of Polymerase Eta,Confirmatory,,
677,588627,1,1,,46500618,785,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that activate MrgX1 receptor signaling,Screening,,
678,588675,1,1,,46500618,785,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that allosterically activate MrgX1 receptor signaling,Screening,,
679,588676,1,1,,46500618,785,Inactive,195969650.0,259249.0,,,Primary cell-based high-throughput screening for identification of compounds that antagonize MrgX1 receptor signaling,Screening,,
680,588795,1,1,,90340863,785,Inconclusive,4758356.0,2237.0,3.7686,Potency,qHTS Assay for the Inhibitors of Human Flap endonuclease 1 (FEN1).,Confirmatory,,
681,588812,1,1,,17389853,785,Unspecified,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
682,588812,1,1,1.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
683,588812,1,1,2.0,17389853,785,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
684,588812,1,1,3.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
685,588812,1,1,4.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
686,588812,1,1,5.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
687,588812,1,1,6.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
688,588812,1,1,7.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
689,588812,1,1,8.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
690,588812,1,1,9.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
691,588812,1,1,10.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
692,588812,1,1,11.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
693,588812,1,1,12.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
694,588812,1,1,13.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
695,588812,1,1,14.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
696,588812,1,1,15.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
697,588812,1,1,16.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
698,588812,1,1,17.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
699,588812,1,1,18.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
700,588812,1,1,19.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
701,588812,1,1,20.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
702,588812,1,1,21.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
703,588812,1,1,22.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
704,588812,1,1,23.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
705,588812,1,1,24.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
706,588812,1,1,25.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
707,588812,1,1,26.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
708,588812,1,1,27.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
709,588812,1,1,28.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
710,588812,1,1,29.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
711,588812,1,1,30.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
712,588812,1,1,31.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
713,588812,1,1,32.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
714,588812,1,1,33.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
715,588812,1,1,34.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
716,588812,1,1,35.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
717,588812,1,1,36.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
718,588812,1,1,37.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
719,588812,1,1,38.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
720,588812,1,1,39.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
721,588812,1,1,40.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
722,588812,1,1,41.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
723,588812,1,1,42.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
724,588812,1,1,43.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
725,588812,1,1,44.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
726,588812,1,1,45.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
727,588812,1,1,46.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
728,588812,1,1,47.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
729,588812,1,1,48.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
730,588812,1,1,49.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
731,588812,1,1,50.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
732,588812,1,1,51.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
733,588812,1,1,52.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
734,588812,1,1,53.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
735,588812,1,1,54.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
736,588812,1,1,55.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
737,588812,1,1,56.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
738,588812,1,1,57.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
739,588812,1,1,58.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
740,588812,1,1,59.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
741,588812,1,1,60.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
742,588812,1,1,61.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
743,588812,1,1,62.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
744,588812,1,1,63.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
745,588812,1,1,64.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
746,588812,1,1,65.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
747,588812,1,1,66.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
748,588812,1,1,67.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
749,588812,1,1,68.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
750,588812,1,1,69.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
751,588812,1,1,70.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
752,588812,1,1,71.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
753,588812,1,1,72.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
754,588812,1,1,73.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
755,588812,1,1,74.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
756,588812,1,1,75.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
757,588812,1,1,76.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
758,588812,1,1,77.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
759,588812,1,1,78.0,17389853,785,Active,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
760,588812,1,1,79.0,17389853,785,Inactive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
761,588812,1,1,80.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
762,588812,1,1,81.0,17389853,785,Inconclusive,,,,,Cell Viability Profiling of Human Lymphoblast Cell Lines,Other,,
763,588813,1,1,,17389853,785,Unspecified,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
764,588813,1,1,1.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
765,588813,1,1,2.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
766,588813,1,1,3.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
767,588813,1,1,4.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
768,588813,1,1,5.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
769,588813,1,1,6.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
770,588813,1,1,7.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
771,588813,1,1,8.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
772,588813,1,1,9.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
773,588813,1,1,10.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
774,588813,1,1,11.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
775,588813,1,1,12.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
776,588813,1,1,13.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
777,588813,1,1,14.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
778,588813,1,1,15.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
779,588813,1,1,16.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
780,588813,1,1,17.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
781,588813,1,1,18.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
782,588813,1,1,19.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
783,588813,1,1,20.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
784,588813,1,1,21.0,17389853,785,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
785,588813,1,1,22.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
786,588813,1,1,23.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
787,588813,1,1,24.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
788,588813,1,1,25.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
789,588813,1,1,26.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
790,588813,1,1,27.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
791,588813,1,1,28.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
792,588813,1,1,29.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
793,588813,1,1,30.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
794,588813,1,1,31.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
795,588813,1,1,32.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
796,588813,1,1,33.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
797,588813,1,1,34.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
798,588813,1,1,35.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
799,588813,1,1,36.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
800,588813,1,1,37.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
801,588813,1,1,38.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
802,588813,1,1,39.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
803,588813,1,1,40.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
804,588813,1,1,41.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
805,588813,1,1,42.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
806,588813,1,1,43.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
807,588813,1,1,44.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
808,588813,1,1,45.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
809,588813,1,1,46.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
810,588813,1,1,47.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
811,588813,1,1,48.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
812,588813,1,1,49.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
813,588813,1,1,50.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
814,588813,1,1,51.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
815,588813,1,1,52.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
816,588813,1,1,53.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
817,588813,1,1,54.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
818,588813,1,1,55.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
819,588813,1,1,56.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
820,588813,1,1,57.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
821,588813,1,1,58.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
822,588813,1,1,59.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
823,588813,1,1,60.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
824,588813,1,1,61.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
825,588813,1,1,62.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
826,588813,1,1,63.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
827,588813,1,1,64.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
828,588813,1,1,65.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
829,588813,1,1,66.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
830,588813,1,1,67.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
831,588813,1,1,68.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
832,588813,1,1,69.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
833,588813,1,1,70.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
834,588813,1,1,71.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
835,588813,1,1,72.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
836,588813,1,1,73.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
837,588813,1,1,74.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
838,588813,1,1,75.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
839,588813,1,1,76.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
840,588813,1,1,77.0,17389853,785,Inactive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
841,588813,1,1,78.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
842,588813,1,1,79.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
843,588813,1,1,80.0,17389853,785,Active,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
844,588813,1,1,81.0,17389853,785,Inconclusive,,,,,Caspase-3/7 Activation Profiling of Human Lymphoblast Cell Lines,Other,,
845,588834,2,1,,17389853,785,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
846,588834,2,1,,50105477,785,Inactive,325651834.0,3757.0,,Potency,qHTS Assay for Small Molecule Inhibitors of the Human hERG Channel Activity,Confirmatory,,
847,602314,1,2,,92124719,785,Inactive,151220867.0,,,,A screen for compounds that modulate the activity of the Staphylococcus aureus MgrA protein,Other,,
848,602332,1,1,,90340863,785,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
849,602332,1,1,,104171174,785,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
850,602332,1,1,,124880354,785,Inactive,168984549.0,,,Potency,qHTS for Inducers of the Endoplasmic Reticulum Stress Response (ERSR) in Human Glioma: qHTS,Confirmatory,,
851,602813,1,5,,103176079,785,Inactive,,,,,Inhibition of Sarcoplasmic/endoplasmic reticulum calcium ATPase in rabbit hind leg tissue microsomes assessed as rate of NADH oxidation coupled to SERCA-catalyzed ATP hydrolysis at <100 uM by spectroscopic assay,Other,21353727.0,
852,603955,1,3,,103176079,785,Unspecified,,,,,"In-vivo blood to lung partition coefficients of the compound, logP(lung) in rat",Other,17544548.0,
853,607497,6,5,,103176079,785,Active,123910379.0,,5.93,Ki,Inhibition of Dicentrarchus labrax CA using 4-nitrophenylacetate substrate by esterase assay,Confirmatory,21669522.0,
854,624030,1,2,,104171174,785,Inactive,160794.0,,,Potency,Biochemical firefly luciferase enzyme assay for NPC,Confirmatory,,
855,624031,1,2,,104171174,785,Inconclusive,,,36.1254,Potency,S16 Schwann cell viability assay (CellTiter-Glo assay),Confirmatory,,
856,624032,1,2,,104171174,785,Inconclusive,8393992.0,24660.0,4.0533,Potency,S16 Schwann cell PMP22 intronic element firefly luciferase assay,Confirmatory,,
857,624044,1,2,,104171174,785,Active,8393992.0,24660.0,19.9375,Potency,S16 Schwann cell PMP22 intronic element beta-lactamase assay,Confirmatory,,
858,624146,1,1,,90340863,785,Active,71051501.0,2744.0,2.5119,Potency,qHTS for Inhibitors of Glutaminase (GLS): LOPAC Validation,Confirmatory,,
859,624147,1,1,,90340863,785,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors: LOPAC Validation,Confirmatory,,
860,624148,1,2,,90340863,785,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists: LOPAC Validation,Confirmatory,,
861,624149,1,1,,90340863,785,Active,693842.0,4780.0,18.3564,Potency,qHTS of Nrf2 Activators: LOPAC Validation,Confirmatory,,
862,624170,1,1,,104171174,785,Inactive,71051501.0,2744.0,11.2202,Potency,qHTS for Inhibitors of Glutaminase (GLS),Confirmatory,,
863,624172,1,1,,104171174,785,Inactive,1724069.0,2740.0,,Potency,qHTS of GLP-1 Receptor Agonists,Confirmatory,,
864,624173,1,3,,104171174,785,Inactive,62359610.0,,,Potency,qHTS of Trypanosoma Brucei Inhibitors,Confirmatory,,
865,624296,1,1,,17389853,785,Inconclusive,7705682.0,51053.0,7.8467,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
866,624296,1,1,,104171174,785,Inconclusive,7705682.0,51053.0,16.7889,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in MCF 10a normal breast cells.,Confirmatory,,
867,624297,1,1,,17389853,785,Inactive,7705682.0,51053.0,,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
868,624297,1,1,,104171174,785,Inconclusive,7705682.0,51053.0,13.9537,Potency,A quantitative high throughput screen for small molecules that induce DNA re-replication in SW480 colon adenocarcinoma cells.,Confirmatory,,
869,624349,1,2,,92124719,785,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
870,624349,1,2,,92307918,785,Inactive,,,,,A screen for compounds that inhibit liver stage malaria,Other,,
871,624455,1,1,,90340863,785,Inactive,299681.0,1812.0,,Potency,HTS Assay for Allosteric Antagonists of the Human D2 Dopamine Receptor: Hit Validation in HTRF,Confirmatory,,
872,624610,1,9,,103176079,785,Unspecified,30173486.0,54577.0,,,Specific activity of expressed human recombinant UGT1A7,Other,10836148.0,
873,624613,1,9,,103176079,785,Unspecified,29839636.0,54575.0,,,Specific activity of expressed human recombinant UGT1A10,Other,10836148.0,
874,651631,4,1,,144203720,785,Inconclusive,269849759.0,7157.0,33.4915,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
875,651631,4,1,,144209543,785,Inconclusive,269849759.0,7157.0,30.451,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
876,651631,4,1,,144210335,785,Inconclusive,269849759.0,7157.0,27.305999999999997,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway,Confirmatory,,
877,651632,4,1,,144203720,785,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
878,651632,4,1,,144209543,785,Inconclusive,296439460.0,79915.0,54.1504,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
879,651632,4,1,,144210335,785,Inactive,296439460.0,79915.0,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5,Confirmatory,,
880,651633,4,1,,144203720,785,Active,,,21.1317,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
881,651633,4,1,,144209543,785,Active,,,13.602,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
882,651633,4,1,,144210335,785,Active,,,17.2289,Potency-Replicate_1,qHTS assay for small molecule agonists of the p53 signaling pathway - cell viability,Confirmatory,,
883,651634,4,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
884,651634,4,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
885,651634,4,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5 - cell viability,Confirmatory,,
886,651635,1,3,,90340863,785,Inconclusive,171543895.0,6311.0,39.8107,Potency,qHTS for Inhibitors of ATXN expression,Confirmatory,,
887,651741,1,1,,17389853,785,Active,20149576.0,4780.0,2.1132,Potency,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
888,651743,1,1,,17389853,785,Inconclusive,269849759.0,7157.0,,Potency,qHTS assay for small molecule activators of the p53 signaling pathway,Confirmatory,,
889,651749,1,1,,17389853,785,Inactive,34577122.0,4790.0,,Potency,qHTS assay for small molecule activators of the nuclear factor-kappa B (NF-kB) signaling pathway,Confirmatory,,
890,651751,1,1,,17389853,785,Inactive,5702233.0,84385.0,,Potency,qHTS assay for small molecule activators of the rat pregnane X receptor (rPXR) signaling pathway,Confirmatory,,
891,651754,1,1,,17389853,785,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 1 hr assay,Confirmatory,,
892,651755,1,1,,17389853,785,Inactive,,,,Potency,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - 5 hr assay,Confirmatory,,
893,651757,1,1,,17389853,785,Inconclusive,25952111.0,7124.0,,Potency,qHTS assay to identify small molecules that stimulate Tumor Necrosis Factor-alpha (TNF-alpha) secretion,Confirmatory,,
894,651758,1,1,,17389853,785,Active,186368.0,3576.0,66.8242,Potency,qHTS assay to identify small molecules that stimulate interleukin-8 (IL-8) secretion,Confirmatory,,
895,651777,1,1,,17389853,785,Inconclusive,51095037.0,196.0,56.2341,Potency,qHTS assay for environmental chemicals that activate the Aryl hydrocarbon Receptor (AhR) signaling pathway,Confirmatory,,
896,651778,1,1,,17389853,785,Inactive,3041727.0,5465.0,,Potency,qHTS assay for small molecule agonists of the peroxisome proliferator-activated receptor alpha (PPARalpha) signaling pathway,Confirmatory,,
897,651802,1,1,,17389853,785,Active,49066040.0,6097.0,10.5909,Potency,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
898,651828,1,2,,121361200,785,Inactive,127925.0,,,,A screen for compounds that inhibit nucleocapsid/RNA interactions in Rift Valley Fever Virus,Other,,
899,651838,1,1,,17389853,785,Unspecified,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
900,651838,1,1,1.0,17389853,785,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
901,651838,1,1,2.0,17389853,785,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
902,651838,1,1,3.0,17389853,785,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
903,651838,1,1,4.0,17389853,785,Active,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
904,651838,1,1,5.0,17389853,785,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
905,651838,1,1,6.0,17389853,785,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
906,651838,1,1,7.0,17389853,785,Inconclusive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
907,651838,1,1,8.0,17389853,785,Inactive,,,,,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against a panel of isogenic chicken DT40 cell lines with known DNA damage response pathways,Other,,
908,652048,1,2,,144203720,785,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Agonist: qHTS,Screening,,
909,652051,1,1,,144203720,785,Inactive,89191863.0,1814.0,,,qHTS of D3 Dopamine Receptor Potentiators: qHTS,Screening,,
910,652106,1,1,,90340863,785,Inactive,586067.0,6622.0,,Potency,qHTS of alpha-syn Inhibitors,Confirmatory,,
911,662538,2,2,,103176079,785,Active,,,10.02,IC50,Inhibition of mushroom tyrosinase using L-tyrosine as substrate after 20 mins by spectrophotometry,Confirmatory,22579419.0,
912,662540,4,1,,103176079,785,Active,,,4.21,IC50,Depigmentation activity in mouse Melan-a cells after 4 days by spectrophotometry,Confirmatory,22579419.0,
913,662541,4,1,,103176079,785,Active,,,15.0,IC50,Cytotoxicity against mouse Melan-a cells after 4 days by crystal voilet method,Confirmatory,22579419.0,
914,662542,1,2,,103176079,785,Unspecified,,,,,Ratio of IC50 for cytotoxicity against mouse Melan-a cells to IC50 for depigmentation in mouse Melan-a cells,Other,22579419.0,
915,686978,1,1,,124880354,785,Inconclusive,79154014.0,55775.0,16.3601,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
916,686978,1,1,,144203720,785,Inconclusive,79154014.0,55775.0,29.8554,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in absence of CPT,Confirmatory,,
917,686979,1,1,,124880354,785,Active,79154014.0,55775.0,20.5962,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
918,686979,1,1,,144203720,785,Inconclusive,79154014.0,55775.0,26.6086,Potency,qHTS for Inhibitors of human tyrosyl-DNA phosphodiesterase 1 (TDP1): qHTS in cells in presence of CPT,Confirmatory,,
919,687035,1,1,,163564531,785,Inactive,125541954.0,,,,Fluorescence polarization based primary biochemical high throughput screening assay of LOPAC1280 to identify inhibitors of hepatitis C non-structural protein 3 helicase,Screening,,
920,687037,1,3,,163564531,785,Inactive,,,,,Fluorescence-based counterscreen assay of HCV NS3 helicase-DNA binding inhibitors in LOPAC1280: biochemical high-throughput screening assay to identify compounds that enhance or quench fluorescence of a Cy5-DNA-NS3h complex,Screening,,
921,687639,2,3,,103176079,785,Active,,,13.48,IC50,Inhibition of mushroom tyrosinase using as L-tyrosine substrate after 10 mins by spectrophotometric analysis,Confirmatory,21561780.0,
922,687640,2,3,,103176079,785,Unspecified,,,1090.56,IC50,Inhibition of mushroom tyrosinase using as L-DOPA substrate after 2 mins by spectrophotometric analysis,Confirmatory,21561780.0,
923,714144,1,2,,103176079,785,Unspecified,,,,,Antilarval activity against third-instar larvae of Anopheles gambiae assessed as mortality at 1000 ug/L after 72 hrs,Other,22300888.0,
924,714145,1,2,,103176079,785,Unspecified,,,,,Antilarval activity against third-instar larvae of Anopheles gambiae assessed as mortality at 50 ug/L after 72 hrs,Other,22300888.0,
925,714146,1,2,,103176079,785,Unspecified,,,,,Ratio of kcat to Km for Trametes versicolor laccase,Other,22300888.0,
926,714147,2,2,,103176079,785,Active,,,20.0,Km,Activity of Trametes versicolor laccase by spectrophotometric analysis,Confirmatory,22300888.0,
927,720516,2,1,,144203720,785,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
928,720516,2,1,,144209543,785,Inconclusive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
929,720516,2,1,,144210335,785,Inactive,296439460.0,79915.0,,ATAD5 Potency (uM),qHTS assay for small molecules that induce genotoxicity in human embryonic kidney cells expressing luciferase-tagged ATAD5: Summary,Summary,,
930,720532,1,1,,124880354,785,Inconclusive,420597.0,,11.2202,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
931,720532,1,1,,144203720,785,Inconclusive,420597.0,,35.4813,Potency,qHTS for Inhibitors of binding or entry into cells for Marburg Virus,Confirmatory,,
932,720533,1,1,,124880354,785,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
933,720533,1,1,,144203720,785,Inactive,,,,Potency,qHTS for Inhibitors of binding or entry into cells for Lassa Virus,Confirmatory,,
934,720538,1,2,,90340863,785,Inactive,220983390.0,410.0,30.1313,Potency,qHTS screen for enhancers of Arylsulfatase A (ASA1): LOPAC Validation Assay,Confirmatory,,
935,720552,2,1,,144203720,785,Inconclusive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
936,720552,2,1,,144209543,785,Inconclusive,269849759.0,7157.0,56.2689,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
937,720552,2,1,,144210335,785,Inconclusive,269849759.0,7157.0,,Ratio Potency (uM),qHTS assay for small molecule agonists of the p53 signaling pathway: Summary,Summary,,
938,720559,1,2,,90340863,785,Inactive,112927.0,351.0,,Potency,qHTS for compounds that reverse cellular toxicity of Amyloid beta (A-beta) peptide in yeast: LOPAC Validation Assay,Confirmatory,,
939,720572,1,2,,90340863,785,Inactive,3063388.0,5071.0,,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (NLuc Reporter),Confirmatory,,
940,720573,1,2,,90340863,785,Inactive,3063388.0,5071.0,29.0929,Potency,qHTS for Activators of Parkin Expression:  LOPAC Validation Assay (FLuc Reporter),Confirmatory,,
941,720579,2,1,,124880354,785,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: mCherry Reporter Primary qHTS,Confirmatory,,
942,720580,1,1,,124880354,785,Inactive,222762.0,3707576.0,,Potency,qHTS for Stage-Specific Inhibitors of Vaccinia Orthopoxvirus: Venus Reporter Primary qHTS,Confirmatory,,
943,720634,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
944,720634,2,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
945,720634,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential - cell viability,Confirmatory,,
946,720635,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
947,720635,2,1,,144209543,785,Inconclusive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
948,720635,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule disruptors of the mitochondrial membrane potential,Confirmatory,,
949,720636,1,1,,17389853,785,Inconclusive,20149576.0,4780.0,47.3079,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity,Confirmatory,,
950,720637,2,1,,144203720,785,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
951,720637,2,1,,144209543,785,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
952,720637,2,1,,144210335,785,Inactive,,,,Ratio Potency (uM),qHTS assay for small molecule disruptors of the mitochondrial membrane potential: Summary,Summary,,
953,720641,1,2,,92307918,785,Inactive,15923709.0,,,,A screen for compounds that inhibit the activity of LtaS in Staphylococcus aureus,Other,,
954,720652,1,1,,17389853,785,Inconclusive,,,74.97800000000001,Potency-Replicate_1,qHTS assay for small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
955,720653,1,1,,17389853,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway measured by Nrf2-dependant transcriptional activity - cell viability counter screen,Confirmatory,,
956,720659,1,1,,17389853,785,Inactive,325495557.0,8856.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the human pregnane X receptor (PXR) signaling pathway,Confirmatory,,
957,720674,2,2,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
958,720674,2,2,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
959,720674,2,2,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cells,Confirmatory,,
960,720675,2,2,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
961,720675,2,2,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
962,720675,2,2,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cells,Confirmatory,,
963,720678,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
964,720678,2,1,,144209543,785,Inconclusive,,,50.1187,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
965,720678,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cells,Confirmatory,,
966,720679,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
967,720679,2,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
968,720679,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cells,Confirmatory,,
969,720680,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
970,720680,2,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
971,720680,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cells,Confirmatory,,
972,720681,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
973,720681,2,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
974,720681,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HEK293 cell free culture,Confirmatory,,
975,720682,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
976,720682,2,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
977,720682,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HEK293 cell free culture,Confirmatory,,
978,720683,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
979,720683,2,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
980,720683,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HEK293 cell free culture,Confirmatory,,
981,720684,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
982,720684,2,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
983,720684,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 590 nm (red) in HepG2 cell free culture,Confirmatory,,
984,720685,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
985,720685,2,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
986,720685,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cell free culture,Confirmatory,,
987,720686,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
988,720686,2,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
989,720686,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 535 nm (green) in HepG2 cell free culture,Confirmatory,,
990,720687,2,2,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
991,720687,2,2,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
992,720687,2,2,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to test for compound auto fluorescence at 460 nm (blue) in HepG2 cells,Confirmatory,,
993,720691,4,1,,144203720,785,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
994,720691,4,1,,144209543,785,Inactive,311348376.0,2908.0,34.4492,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
995,720691,4,1,,144210335,785,Inactive,311348376.0,2908.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
996,720692,3,1,,144203720,785,Inconclusive,311348376.0,2908.0,53.5378,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
997,720692,3,1,,144209543,785,Inconclusive,311348376.0,2908.0,97.0911,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
998,720692,3,1,,144210335,785,Inconclusive,311348376.0,2908.0,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway,Confirmatory,,
999,720693,3,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1000,720693,3,1,,144209543,785,Active,,,54.5984,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1001,720693,3,1,,144210335,785,Inconclusive,,,54.941,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway - cell viability counter screen,Confirmatory,,
1002,720717,1,3,,92124719,785,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1003,720717,1,3,,92307918,785,Inactive,1718329.0,,,,Chemical Probes of Kaposi's Sarcoma Herpes Virus Latent Infection,Other,,
1004,720719,2,1,,144203720,785,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1005,720719,2,1,,144209543,785,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1006,720719,2,1,,144210335,785,Inactive,311348376.0,2908.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1007,720725,2,1,,144203720,785,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1008,720725,2,1,,144209543,785,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1009,720725,2,1,,144210335,785,Inconclusive,311348376.0,2908.0,,,qHTS assay to identify small molecule antagonists of the glucocorticoid receptor (GR) signaling pathway: Summary,Summary,,
1010,743012,3,1,,144203720,785,Active,,,23.7101,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1011,743012,3,1,,144209543,785,Active,,,9.6295,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1012,743012,3,1,,144210335,785,Active,,,61.1306,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - wild type cell line,Confirmatory,,
1013,743014,3,1,,144203720,785,Active,,,18.8336,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1014,743014,3,1,,144209543,785,Active,,,24.1881,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1015,743014,3,1,,144210335,785,Active,,,48.5577,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rev3 mutant cell line,Confirmatory,,
1016,743015,3,1,,144203720,785,Active,,,26.6032,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1017,743015,3,1,,144209543,785,Active,,,13.602,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1018,743015,3,1,,144210335,785,Active,,,54.4827,Potency-Replicate_1,qHTS assay for identifying genotoxic compounds that show differential cytotoxicity against isogenic chicken DT40 cell lines with known DNA damage response pathways - Rad54/Ku70 mutant cell line,Confirmatory,,
1019,743033,3,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1020,743033,3,1,,144209543,785,Inconclusive,,,38.6527,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1021,743033,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway - cell viability counter screen,Confirmatory,,
1022,743035,2,1,,144203720,785,Inconclusive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1023,743035,2,1,,144209543,785,Inconclusive,124375976.0,367.0,48.6608,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1024,743035,2,1,,144210335,785,Inconclusive,124375976.0,367.0,38.8952,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1025,743036,2,1,,144203720,785,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1026,743036,2,1,,144209543,785,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1027,743036,2,1,,144210335,785,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway,Confirmatory,,
1028,743040,3,1,,144203720,785,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1029,743040,3,1,,144209543,785,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1030,743040,3,1,,144210335,785,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1031,743041,3,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1032,743041,3,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1033,743041,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line - cell viability counter screen,Confirmatory,,
1034,743042,3,1,,144203720,785,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1035,743042,3,1,,144209543,785,Inconclusive,124375976.0,367.0,60.7578,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1036,743042,3,1,,144210335,785,Inactive,124375976.0,367.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen  receptor (AR) signaling pathway using the MDA cell line,Confirmatory,,
1037,743053,2,1,,144203720,785,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1038,743053,2,1,,144209543,785,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1039,743053,2,1,,144210335,785,Inactive,124375976.0,367.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1040,743054,2,1,,144203720,785,Inconclusive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1041,743054,2,1,,144209543,785,Inconclusive,124375976.0,367.0,,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1042,743054,2,1,,144210335,785,Inconclusive,124375976.0,367.0,30.6379,AR Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line: Summary,Summary,,
1043,743063,2,1,,144203720,785,Inconclusive,124375976.0,367.0,26.8325,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1044,743063,2,1,,144209543,785,Inconclusive,124375976.0,367.0,38.6527,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1045,743063,2,1,,144210335,785,Inconclusive,124375976.0,367.0,48.9662,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway: Summary,Summary,,
1046,743064,3,1,,144203720,785,Active,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1047,743064,3,1,,144209543,785,Active,,,17.1239,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1048,743064,3,1,,144210335,785,Active,,,34.3762,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway - cell viability counter screen,Confirmatory,,
1049,743065,3,1,,144203720,785,Active,399498506.0,24831.0,21.1317,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1050,743065,3,1,,144209543,785,Active,399498506.0,24831.0,30.451,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1051,743065,3,1,,144210335,785,Active,399498506.0,24831.0,30.6379,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1052,743066,3,1,,144203720,785,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1053,743066,3,1,,144209543,785,Inactive,399498506.0,24831.0,68.1713,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1054,743066,3,1,,144210335,785,Inconclusive,399498506.0,24831.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid receptor (TR) signaling pathway,Confirmatory,,
1055,743067,2,1,,144203720,785,Inconclusive,399498506.0,24831.0,21.1317,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1056,743067,2,1,,144209543,785,Inconclusive,399498506.0,24831.0,27.1395,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1057,743067,2,1,,144210335,785,Inconclusive,399498506.0,24831.0,29.4844,TR Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid receptor (TR) signaling pathway: Summary,Summary,,
1058,743069,2,1,,144203720,785,Inconclusive,348019627.0,2099.0,10.6822,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1059,743069,2,1,,144209543,785,Inconclusive,348019627.0,2099.0,30.7029,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1060,743069,2,1,,144210335,785,Inconclusive,348019627.0,2099.0,38.8952,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1061,743074,2,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1062,743074,2,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1063,743074,2,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway - cell viability counter screen,Confirmatory,,
1064,743075,2,1,,144203720,785,Inconclusive,348019627.0,2099.0,30.0771,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1065,743075,2,1,,144209543,785,Inconclusive,348019627.0,2099.0,38.6527,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1066,743075,2,1,,144210335,785,Inactive,348019627.0,2099.0,61.6599,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway,Confirmatory,,
1067,743077,2,1,,144203720,785,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1068,743077,2,1,,144209543,785,Inconclusive,348019627.0,2099.0,50.577,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1069,743077,2,1,,144210335,785,Inactive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1070,743078,2,1,,144203720,785,Inconclusive,348019627.0,2099.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1071,743078,2,1,,144209543,785,Inconclusive,348019627.0,2099.0,10.4837,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1072,743078,2,1,,144210335,785,Inconclusive,348019627.0,2099.0,43.6412,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway: Summary,Summary,,
1073,743079,3,1,,144203720,785,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1074,743079,3,1,,144209543,785,Inconclusive,348019627.0,2099.0,30.451,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1075,743079,3,1,,144210335,785,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1076,743080,3,1,,144203720,785,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1077,743080,3,1,,144209543,785,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1078,743080,3,1,,144210335,785,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line,Confirmatory,,
1079,743081,3,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1080,743081,3,1,,144209543,785,Inconclusive,,,60.7578,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1081,743081,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line - cell viability counter screen,Confirmatory,,
1082,743083,3,1,,144203720,785,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1083,743083,3,1,,144209543,785,Active,119597822.0,1588.0,60.7578,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1084,743083,3,1,,144210335,785,Inactive,119597822.0,1588.0,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors,Confirmatory,,
1085,743084,3,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1086,743084,3,1,,144209543,785,Active,,,54.1504,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1087,743084,3,1,,144210335,785,Inconclusive,,,21.6899,Potency-Replicate_1,qHTS assay to identify aromatase inhibitors - cell viability counter screen,Confirmatory,,
1088,743085,3,1,,144203720,785,Inconclusive,51095037.0,196.0,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1089,743085,3,1,,144209543,785,Inconclusive,51095037.0,196.0,38.3356,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1090,743085,3,1,,144210335,785,Inconclusive,51095037.0,196.0,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway,Confirmatory,,
1091,743086,3,1,,144203720,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1092,743086,3,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1093,743086,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway - cell viability counter screen,Confirmatory,,
1094,743091,2,1,,144203720,785,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1095,743091,2,1,,144209543,785,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1096,743091,2,1,,144210335,785,Inactive,348019627.0,2099.0,,ER Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line: Summary,Summary,,
1097,743094,3,1,,144203720,785,Inconclusive,216409692.0,5468.0,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1098,743094,3,1,,144209543,785,Inconclusive,216409692.0,5468.0,19.3722,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1099,743094,3,1,,144210335,785,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1100,743122,2,1,,144203720,785,Inconclusive,51095037.0,196.0,13.3332,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1101,743122,2,1,,144209543,785,Inconclusive,51095037.0,196.0,22.835,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1102,743122,2,1,,144210335,785,Active,51095037.0,196.0,10.0676,AhR Potency (uM),qHTS assay to identify small molecule that activate the aryl hydrocarbon receptor (AhR) signaling pathway: Summary,Summary,,
1103,743139,2,1,,144203720,785,Inactive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1104,743139,2,1,,144209543,785,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1105,743139,2,1,,144210335,785,Inconclusive,119597822.0,1588.0,,,qHTS assay to identify aromatase inhibitors: Summary,Summary,,
1106,743140,2,1,,144203720,785,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1107,743140,2,1,,144209543,785,Inconclusive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1108,743140,2,1,,144210335,785,Inactive,216409692.0,5468.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1109,743191,3,1,,144209543,785,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1110,743191,3,1,,144210335,785,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1111,743191,3,1,,170464661,785,Inconclusive,216409692.0,5468.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway,Confirmatory,,
1112,743194,3,1,,144209543,785,Inconclusive,,,0.4337,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1113,743194,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1114,743194,3,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway - cell viability counter screen,Confirmatory,,
1115,743199,2,1,,144209543,785,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1116,743199,2,1,,144210335,785,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1117,743199,2,1,,170464661,785,Inactive,216409692.0,5468.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor gamma (PPARg) signaling pathway: Summary,Summary,,
1118,743202,4,1,,144209543,785,Inconclusive,20149576.0,4780.0,0.5415,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1119,743202,4,1,,144210335,785,Inconclusive,20149576.0,4780.0,1.3685,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1120,743202,4,1,,170464661,785,Inconclusive,20149576.0,4780.0,2.113,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway,Confirmatory,,
1121,743203,3,1,,144209543,785,Inconclusive,,,68.1713,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1122,743203,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1123,743203,3,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway - cell viability counter screen,Confirmatory,,
1124,743205,1,1,,90340863,785,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1125,743205,1,1,,90340863,785,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: Diaphorase-coupled assay,Confirmatory,,
1126,743206,1,1,,90340863,785,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1127,743206,1,1,,90340863,785,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: ADP-Glo assay,Confirmatory,,
1128,743207,1,1,,90340863,785,Inactive,4503951.0,2645.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1129,743207,1,1,,90340863,785,Inactive,221625433.0,2646.0,,Potency,qHTS assay for inhibitors of recombinant human GCK-GKRP interaction: HTRF assay,Confirmatory,,
1130,743209,3,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1131,743209,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1132,743209,3,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway - cell viability counter screen,Confirmatory,,
1133,743210,4,1,,144209543,785,Inconclusive,4504517.0,3315.0,17.2655,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1134,743210,4,1,,144210335,785,Inactive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1135,743210,4,1,,170464661,785,Inconclusive,4504517.0,3315.0,,Potency-Replicate_1,qHTS assay for small molecule activators of the heat shock response signaling pathway,Confirmatory,,
1136,743211,3,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1137,743211,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1138,743211,3,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1139,743212,3,1,,144209543,785,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1140,743212,3,1,,144210335,785,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1141,743212,3,1,,170464661,785,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1142,743213,3,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1143,743213,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1144,743213,3,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway - cell viability counter screen,Confirmatory,,
1145,743215,3,1,,144209543,785,Inconclusive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1146,743215,3,1,,144210335,785,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1147,743215,3,1,,170464661,785,Inactive,216409690.0,5467.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway,Confirmatory,,
1148,743217,3,1,,144209543,785,Inconclusive,325495553.0,9971.0,21.736,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1149,743217,3,1,,144210335,785,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1150,743217,3,1,,170464661,785,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1151,743218,3,1,,144209543,785,Inconclusive,,,0.0434,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1152,743218,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1153,743218,3,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1154,743219,3,1,,144209543,785,Active,20149576.0,4780.0,1.41341,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1155,743219,3,1,,144210335,785,Active,20149576.0,4780.0,1.3685399999999999,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1156,743219,3,1,,170464661,785,Active,20149576.0,4780.0,2.28157,Ratio Potency (uM),qHTS assay for small molecule agonists of the antioxidant response element (ARE) signaling pathway: Summary,Summary,,
1157,743220,3,1,,144209543,785,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1158,743220,3,1,,144210335,785,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1159,743220,3,1,,170464661,785,Inactive,325495553.0,9971.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway,Confirmatory,,
1160,743221,3,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1161,743221,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1162,743221,3,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway - cell viability counter screen,Confirmatory,,
1163,743222,3,1,,144209543,785,Inconclusive,216409708.0,7421.0,6.126,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1164,743222,3,1,,144210335,785,Inconclusive,216409708.0,7421.0,48.9662,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1165,743222,3,1,,170464661,785,Inconclusive,216409708.0,7421.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1166,743223,3,1,,144209543,785,Inconclusive,216409708.0,7421.0,5.4598,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1167,743223,3,1,,144210335,785,Inconclusive,216409708.0,7421.0,21.8724,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1168,743223,3,1,,170464661,785,Inconclusive,216409708.0,7421.0,18.9959,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway,Confirmatory,,
1169,743224,3,1,,144209543,785,Inconclusive,,,61.2604,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1170,743224,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1171,743224,3,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1172,743225,3,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1173,743225,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1174,743225,3,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway - cell viability counter screen,Confirmatory,,
1175,743226,2,1,,144209543,785,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1176,743226,2,1,,144210335,785,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1177,743226,2,1,,170464661,785,Inactive,216409690.0,5467.0,,,qHTS assay to identify small molecule antagonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1178,743227,2,1,,144209543,785,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1179,743227,2,1,,144210335,785,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1180,743227,2,1,,170464661,785,Inactive,216409690.0,5467.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the peroxisome proliferator-activated receptor delta (PPARd) signaling pathway: Summary,Summary,,
1181,743228,3,1,,144209543,785,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1182,743228,3,1,,144210335,785,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1183,743228,3,1,,170464661,785,Inactive,4504517.0,3315.0,,Ratio Potency (uM),qHTS assay for small molecule activators of the heat shock response signaling pathway: Summary,Summary,,
1184,743239,2,1,,144209543,785,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1185,743239,2,1,,144210335,785,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1186,743239,2,1,,170464661,785,Inactive,325495553.0,9971.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1187,743240,2,1,,144209543,785,Inconclusive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1188,743240,2,1,,144210335,785,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1189,743240,2,1,,170464661,785,Inactive,325495553.0,9971.0,,,qHTS assay to identify small molecule antagonists of the farnesoid-X-receptor (FXR) signaling pathway: Summary,Summary,,
1190,743241,2,1,,144209543,785,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1191,743241,2,1,,144210335,785,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1192,743241,2,1,,170464661,785,Inactive,216409708.0,7421.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1193,743242,2,1,,144209543,785,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1194,743242,2,1,,144210335,785,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1195,743242,2,1,,170464661,785,Inconclusive,216409708.0,7421.0,,,qHTS assay to identify small molecule antagonists of the vitamin D receptor (VDR) signaling pathway: Summary,Summary,,
1196,743244,1,1,,90340863,785,Inconclusive,,,5.6234,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1197,743244,1,1,,144203720,785,Inconclusive,,,22.3872,Potency,qHTS Assay for Identifying Gametocytocidal Compounds,Confirmatory,,
1198,743288,1,1,,17389853,785,Inactive,,,,Potency,qHTS assay for cell viability of HEK293 cells,Confirmatory,,
1199,743292,1,1,,17389853,785,Inconclusive,,,70.7946,Potency,qHTS assay for cell viability of the p53RE-bla HCT-116 cell line,Confirmatory,,
1200,761678,1,5,,103176079,785,Active,6686057.0,,,,Inhibition of mushroom tyrosinase using L-tyrosine as substrate at 23 uM after 30 mins by spectrophotometric analysis,Other,23796767.0,
1201,947227,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R040825,Other,,
1202,947228,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R040825,Other,,
1203,947229,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R040825,Other,,
1204,947230,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R040825,Other,,
1205,947231,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R040825,Other,,
1206,947232,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R040825,Other,,
1207,947233,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R040825,Other,,
1208,947234,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R040825,Other,,
1209,947235,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R040825,Other,,
1210,947236,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R040825,Other,,
1211,947237,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R040825,Other,,
1212,947238,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R040825,Other,,
1213,947239,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R040825,Other,,
1214,948204,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HCT (Hematocrit); Study_ID: R040825,Other,,
1215,948205,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: RBC (Erythrocytes); Study_ID: R040825,Other,,
1216,948206,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: WBC (Leukocytes); Study_ID: R040825,Other,,
1217,948207,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: LYMLE (Lymphocytes/Leukocytes); Study_ID: R040825,Other,,
1218,948208,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: PLAT (Platelets); Study_ID: R040825,Other,,
1219,948209,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: EOSLE (Eosinophils/Leukocytes); Study_ID: R040825,Other,,
1220,948210,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: NEUTLE (Neutrophils/Leukocytes); Study_ID: R040825,Other,,
1221,948211,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MONOLE (Monocytes/Leukocytes); Study_ID: R040825,Other,,
1222,948212,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCH (Ery. Mean Corpuscular Hemoglobin); Study_ID: R040825,Other,,
1223,948213,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: HGB (Hemoglobin); Study_ID: R040825,Other,,
1224,948214,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: BASOLE (Basophils/Leukocytes); Study_ID: R040825,Other,,
1225,948215,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCHC (Ery. Mean Corpuscular HGB Concentration); Study_ID: R040825,Other,,
1226,948216,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Hematology; Assay: MCV (Ery. Mean Corpuscular Volume); Study_ID: R040825,Other,,
1227,961692,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R040825,Other,,
1228,961693,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R040825,Other,,
1229,961694,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R040825,Other,,
1230,961695,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R040825,Other,,
1231,961696,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R040825,Other,,
1232,962098,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R040825,Other,,
1233,962099,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R040825,Other,,
1234,962100,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R040825,Other,,
1235,962101,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R040825,Other,,
1236,962102,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R040825,Other,,
1237,962103,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R040825,Other,,
1238,962104,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R040825,Other,,
1239,962105,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R040825,Other,,
1240,962106,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R040825,Other,,
1241,962107,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R040825,Other,,
1242,962108,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R040825,Other,,
1243,962109,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R040825,Other,,
1244,962110,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R040825,Other,,
1245,962111,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R040825,Other,,
1246,969298,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALT (Alanine Aminotransferase); Study_ID: R040825,Other,,
1247,969299,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHLORIDE (Chloride); Study_ID: R040825,Other,,
1248,969300,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CHOL (Cholesterol); Study_ID: R040825,Other,,
1249,969301,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: SODIUM (Sodium); Study_ID: R040825,Other,,
1250,969302,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CREAT (Creatinine); Study_ID: R040825,Other,,
1251,969303,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: GLUC (Glucose); Study_ID: R040825,Other,,
1252,969304,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LDH (Lactate Dehydrogenase); Study_ID: R040825,Other,,
1253,969305,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: POTASSIUM (Potassium); Study_ID: R040825,Other,,
1254,969306,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALB (Albumin); Study_ID: R040825,Other,,
1255,969307,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BUN (Blood Urea Nitrogen); Study_ID: R040825,Other,,
1256,969308,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: BILI (Bilirubin); Study_ID: R040825,Other,,
1257,969309,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: ALP (Alkaline Phosphatase); Study_ID: R040825,Other,,
1258,969310,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PROT (Protein); Study_ID: R040825,Other,,
1259,969311,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: PHOS (Phosphate); Study_ID: R040825,Other,,
1260,969312,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CO2 (Carbon Dioxide); Study_ID: R040825,Other,,
1261,969313,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: CK (Creatine Kinase); Study_ID: R040825,Other,,
1262,969314,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: URATE (Urate); Study_ID: R040825,Other,,
1263,969315,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: AST (Aspartate Aminotransferase); Study_ID: R040825,Other,,
1264,969316,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Biochemistry; Assay: LIPASE (Triacylglycerol Lipase); Study_ID: R040825,Other,,
1265,977599,1,1,,103176079,785,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B1-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
1266,977602,1,2,,103176079,785,Unspecified,,,,,Inhibition of sodium fluorescein uptake in OATP1B3-transfected CHO cells at an equimolar substrate-inhibitor concentration of 10 uM,Other,23571415.0,
1267,977610,3,1,,170484881,785,Active,392935652.0,,0.09,Ki,Experimentally measured binding affinity data (Ki) for protein-ligand complexes derived from PDB,Other,22531842.0,
1268,1005429,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1269,1005430,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: R040825",Other,,
1270,1005431,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: R040825",Other,,
1271,1007293,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: R040825",Other,,
1272,1007294,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: R040825",Other,,
1273,1007295,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R040825",Other,,
1274,1007296,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: R040825",Other,,
1275,1007297,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: R040825,Other,,
1276,1007298,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1277,1007299,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1278,1007300,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R040825",Other,,
1279,1007301,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: R040825",Other,,
1280,1007302,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: R040825",Other,,
1281,1007303,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: R040825",Other,,
1282,1007304,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: R040825",Other,,
1283,1007305,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R040825",Other,,
1284,1007306,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: R040825",Other,,
1285,1007307,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: R040825,Other,,
1286,1007308,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: R040825",Other,,
1287,1007309,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1288,1007310,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1289,1007311,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: R040825",Other,,
1290,1007312,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: R040825",Other,,
1291,1007313,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: R040825",Other,,
1292,1007314,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: R040825",Other,,
1293,1007315,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: R040825",Other,,
1294,1007316,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1295,1007317,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R040825",Other,,
1296,1007318,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: R040825",Other,,
1297,1007319,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: R040825,Other,,
1298,1007320,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: R040825",Other,,
1299,1007321,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1300,1007322,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: R040825",Other,,
1301,1007323,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: R040825",Other,,
1302,1007324,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: R040825",Other,,
1303,1007325,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1304,1007904,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1305,1007905,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: R040825",Other,,
1306,1007906,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: R040825",Other,,
1307,1007907,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: R040825",Other,,
1308,1007908,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: R040825",Other,,
1309,1007909,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1310,1007910,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: R040825",Other,,
1311,1007911,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: R040825",Other,,
1312,1009778,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: R040825",Other,,
1313,1009779,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1314,1009780,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: R040825",Other,,
1315,1009781,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: R040825",Other,,
1316,1009782,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1317,1009783,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: R040825",Other,,
1318,1009784,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: R040825",Other,,
1319,1009785,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1320,1009786,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: R040825",Other,,
1321,1014730,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1322,1014731,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1323,1014732,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: R040825,Other,,
1324,1014733,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: R040825",Other,,
1325,1014734,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 5 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: R040825",Other,,
1326,1027613,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1327,1027614,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1328,1027615,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Autolysis; Study_ID: R040825,Other,,
1329,1027616,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Fibrosis; Study_ID: R040825",Other,,
1330,1027617,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Myocyte, Degeneration; Study_ID: R040825",Other,,
1331,1027618,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1332,1027619,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Polymorphonuclear Cell; Study_ID: R040825",Other,,
1333,1027620,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Infiltrative Cell, Mononuclear Cell; Study_ID: R040825",Other,,
1334,1027621,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Mineralization; Study_ID: R040825",Other,,
1335,1027622,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Tubule, Regeneration; Study_ID: R040825",Other,,
1336,1028205,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Fibrosis; Study_ID: R040825",Other,,
1337,1028206,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Tubule, Dilatation; Study_ID: R040825",Other,,
1338,1028207,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Nephropathy; Study_ID: R040825,Other,,
1339,1030079,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1340,1030080,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1341,1030081,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Degeneration; Study_ID: R040825",Other,,
1342,1030082,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Myocyte, Lipid Accumulation; Study_ID: R040825",Other,,
1343,1030083,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Inflammation, Chronic; Study_ID: R040825",Other,,
1344,1030084,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Mineralization; Study_ID: R040825",Other,,
1345,1030085,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Necrosis; Study_ID: R040825",Other,,
1346,1030086,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Degeneration; Study_ID: R040825",Other,,
1347,1030087,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Edema; Study_ID: R040825",Other,,
1348,1030088,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Single Hepatocyte Necrosis; Study_ID: R040825,Other,,
1349,1030089,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Fibrosis; Study_ID: R040825",Other,,
1350,1030090,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1351,1030091,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Atrium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1352,1030092,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Vacuolation; Study_ID: R040825",Other,,
1353,1030093,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Interstitium, Fibrosis; Study_ID: R040825",Other,,
1354,1030094,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Mineralization; Study_ID: R040825",Other,,
1355,1030095,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Papilla, Cyst(S); Study_ID: R040825",Other,,
1356,1030096,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Epicardium, Hyperplasia; Study_ID: R040825",Other,,
1357,1030097,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1358,1030098,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Necrosis, Fibrinoid; Study_ID: R040825",Other,,
1359,1030099,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Perivascular Fibrosis; Study_ID: R040825",Other,,
1360,1030100,1,3,,103176079,785,Unspecified,,,,,DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Liver; Assay: Nuclear Cytoplasmic Condensation; Study_ID: R040825,Other,,
1361,1030101,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Dilatation; Study_ID: R040825",Other,,
1362,1030102,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1363,1030103,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Myocyte, Degeneration; Study_ID: R040825",Other,,
1364,1030104,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Inflammation, Subacute; Study_ID: R040825",Other,,
1365,1030105,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Urothelial Hyperplasia; Study_ID: R040825",Other,,
1366,1030106,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Papillary Muscle, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1367,1030107,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Deposit; Study_ID: R040825",Other,,
1368,1030108,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Pelvis, Dilatation; Study_ID: R040825",Other,,
1369,1030109,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Hyaline Droplets; Study_ID: R040825",Other,,
1370,1030110,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Tubule, Necrosis; Study_ID: R040825",Other,,
1371,1030111,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Endocardium, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1372,1030695,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Intramyocardial Arteries, Tunica Media, Hypertrophy; Study_ID: R040825",Other,,
1373,1030696,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Cortex, Cyst(S); Study_ID: R040825",Other,,
1374,1030697,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Atrium, Myocyte, Degeneration; Study_ID: R040825",Other,,
1375,1030698,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Right Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1376,1030699,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Medulla, Cyst(S); Study_ID: R040825",Other,,
1377,1030700,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Regeneration; Study_ID: R040825",Other,,
1378,1030701,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1379,1030702,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Cellular Infiltrate, Mononuclear Cell; Study_ID: R040825",Other,,
1380,1032571,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Fibrosis; Study_ID: R040825",Other,,
1381,1032572,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Interventricular Septum, Myocyte, Degeneration; Study_ID: R040825",Other,,
1382,1032573,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Heart; Assay: Left Ventricle, Cellular Infiltrate, Mixed Cell; Study_ID: R040825",Other,,
1383,1032574,1,3,,103176079,785,Unspecified,,,,,"DrugMatrix: Regimen: Daily Repeat; Time: 3 day; Dose: High; Vehicle: .5 % cmc; Route: oral gavage | Dataset: Pathology; Tissue: Kidney; Assay: Tubule, Cast, Proteinaceous; Study_ID: R040825",Other,,
1384,1116055,1,2,,103176079,785,Active,,,,,Inhibition of monophenolase activity of mushroom tyrosinase using L-tyrosine as substrate after 30 min by dopachrome method,Other,,
1385,1117298,1,2,,170464661,785,Inactive,,,28.1838,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 green channel",Confirmatory,,
1386,1117304,1,2,,170464661,785,Inactive,,,3.1623,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 blue channel",Confirmatory,,
1387,1117305,1,2,,170464661,785,Inactive,,,5.6234,AC50 (uM),"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus, Screen 2 ratio channel",Confirmatory,,
1388,1117310,1,1,,170464661,785,Inactive,,,28.1838,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, green channel",Confirmatory,,
1389,1117312,1,1,,170464661,785,Inactive,,,5.62341,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen2, ratio channel",Confirmatory,,
1390,1117314,1,1,,170464661,785,Inactive,,,3.16228,Ac50,"qHTS Assay for Identifying Compounds that block Entry of Ebola Virus: Screen 2, blue channel",Confirmatory,,
1391,1117324,1,1,,170464661,785,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture nuclear area decrease (viability)-IC50,Confirmatory,,
1392,1117326,1,1,,170464661,785,Inactive,,,,,nuclear beta catenin stimulation in WNT3A conditioned C2C12 cells-screen,Screening,,
1393,1117331,1,1,,170464661,785,Inactive,,,33.33,IC50,insulin secretion from INS-1E cells in the presence of 5 mM glucose-IC50,Confirmatory,,
1394,1117336,1,1,,170464661,785,Inactive,,,,,GSK3B-pretreated HCT116 viability from Cell TiterGlo-screen,Screening,,
1395,1117337,1,1,,170464661,785,Inactive,,,10.0,IC50,VEGF stimulated ADSC/ECFC co-culture CD31-stained tube area decrease-IC50,Confirmatory,,
1396,1117342,1,1,,170464661,785,Inactive,,,,,HCT116 viability from Cell TiterGlo-screen,Screening,,
1397,1117343,1,1,,170464661,785,Inactive,,,,,SW480 viability from Cell TiterGlo-screen,Screening,,
1398,1117344,1,1,,170464661,785,Inactive,,,40.0,IC50,GLP1 secretion from NCI-H716 cells-IC50,Confirmatory,,
1399,1117345,1,1,,170464661,785,Active,,,1.0056,IC50,GLP1 secretion from STC-1 cells-IC50,Confirmatory,,
1400,1117346,1,1,,170464661,785,Inactive,,,,,DLD-1 viability from Cell TiterGlo-screen,Screening,,
1401,1121261,1,1,,103176079,785,Unspecified,,,,,Cytotoxicity against human HL60 cells assessed as cell viability up to 120 uM after 24 hrs by trypan blue assay,Other,,
1402,1121263,1,2,,103176079,785,Unspecified,,,,,Antioxidant activity assessed as DPPH radical scavenging rate constant measured for 60 secs by spectrophotometric analysis,Other,,
1403,1159509,1,1,,144209543,785,Inconclusive,119626539.0,4790.0,43.369,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1404,1159509,1,1,,144210335,785,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1405,1159509,1,1,,170464661,785,Inactive,119626539.0,4790.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway,Confirmatory,,
1406,1159515,1,1,,144209543,785,Inconclusive,,,21.736,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1407,1159515,1,1,,144210335,785,Inconclusive,,,34.6654,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1408,1159515,1,1,,170464661,785,Inconclusive,,,23.9145,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the NFkB signaling pathway - cell viability counter screen,Confirmatory,,
1409,1159516,1,1,,144209543,785,Inconclusive,119611100.0,22926.0,24.3882,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1410,1159516,1,1,,144210335,785,Inconclusive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1411,1159516,1,1,,170464661,785,Inconclusive,119611100.0,22926.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway,Confirmatory,,
1412,1159517,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1413,1159517,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1414,1159517,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway - cell viability counter screen,Confirmatory,,
1415,1159518,1,1,,144209543,785,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1416,1159518,1,1,,144210335,785,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1417,1159518,1,1,,170464661,785,Inactive,119626539.0,4790.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the NFkB signaling pathway: Summary,Summary,,
1418,1159519,1,1,,144209543,785,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1419,1159519,1,1,,144210335,785,Inactive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1420,1159519,1,1,,170464661,785,Inconclusive,119611100.0,22926.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the endoplasmic reticulum stress response signaling pathway: Summary,Summary,,
1421,1159520,1,1,,144209543,785,Inconclusive,,,21.5577,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1422,1159520,1,1,,144210335,785,Inconclusive,,,27.305999999999997,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1423,1159520,1,1,,170464661,785,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway - cell viability counter screen,Confirmatory,,
1424,1159521,1,1,,144209543,785,Active,15928672.0,19885.0,21.5577,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1425,1159521,1,1,,144210335,785,Active,15928672.0,19885.0,38.5708,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1426,1159521,1,1,,170464661,785,Active,15928672.0,19885.0,23.7101,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway,Confirmatory,,
1427,1159523,1,1,,144209543,785,Inconclusive,15928672.0,19885.0,21.9753,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1428,1159523,1,1,,144210335,785,Inconclusive,15928672.0,19885.0,38.5708,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1429,1159523,1,1,,170464661,785,Inconclusive,15928672.0,19885.0,26.6032,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoid-related orphan receptor gamma (ROR-gamma) signaling pathway: Summary,Summary,,
1430,1159524,1,1,,124880354,785,Inactive,,,,Potency,High Throughput Screening for Foot and Mouth Disease Virus Antivirals,Confirmatory,,
1431,1159525,1,1,,144209543,785,Inconclusive,,,61.2604,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1432,1159525,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1433,1159525,1,1,,170464661,785,Inconclusive,,,26.8325,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway - cell viability counter screen,Confirmatory,,
1434,1159526,1,1,,144209543,785,Inconclusive,119627033.0,3725.0,21.736,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1435,1159526,1,1,,144210335,785,Inconclusive,119627033.0,3725.0,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1436,1159526,1,1,,170464661,785,Inactive,119627033.0,3725.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the AP-1 signaling pathway,Confirmatory,,
1437,1159527,1,1,,144209543,785,Inconclusive,325495497.0,6256.0,61.2604,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1438,1159527,1,1,,144210335,785,Inconclusive,325495497.0,6256.0,61.6448,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1439,1159527,1,1,,170464661,785,Inactive,325495497.0,6256.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway,Confirmatory,,
1440,1159528,1,1,,144209543,785,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1441,1159528,1,1,,144210335,785,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1442,1159528,1,1,,170464661,785,Inactive,119627033.0,3725.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the AP-1 signaling pathway: Summary,Summary,,
1443,1159529,1,1,,144209543,785,Inconclusive,,,54.5984,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1444,1159529,1,1,,144210335,785,Inconclusive,,,54.941,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1445,1159529,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the RXR signaling pathway - cell viability counter screen,Confirmatory,,
1446,1159531,1,1,,144209543,785,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1447,1159531,1,1,,144210335,785,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1448,1159531,1,1,,170464661,785,Inactive,325495497.0,6256.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the RXR signaling pathway: Summary,Summary,,
1449,1159550,3,1,,252401538,785,Inactive,12653201.0,5226.0,,,Human Phosphogluconate dehydrogenase (6PGD) Inhibitor Screening,Screening,26479318.0,
1450,1159551,1,1,,144209543,785,Inconclusive,,,76.4895,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1451,1159551,1,1,,144210335,785,Inconclusive,,,76.9588,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1452,1159551,1,1,,170464661,785,Inconclusive,,,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoid acid receptor (RAR) signaling pathway - cell viability counter screen,Confirmatory,,
1453,1159552,1,1,,144209543,785,Active,325495463.0,5914.0,17.1239,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1454,1159552,1,1,,144210335,785,Active,325495463.0,5914.0,24.3365,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1455,1159552,1,1,,170464661,785,Active,325495463.0,5914.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1456,1159553,2,1,,144209543,785,Inconclusive,325495463.0,5914.0,15.2617,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1457,1159553,2,1,,144210335,785,Inconclusive,325495463.0,5914.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1458,1159553,2,1,,170464661,785,Inactive,325495463.0,5914.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the retinoic acid receptor (RAR) signaling pathway,Confirmatory,,
1459,1159555,1,1,,144209543,785,Active,325495463.0,5914.0,20.5874,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1460,1159555,1,1,,144210335,785,Active,325495463.0,5914.0,15.956,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1461,1159555,1,1,,170464661,785,Active,325495463.0,5914.0,11.8832,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the retinoic acid receptor (RAR) signaling pathway: Summary,Summary,,
1462,1159580,2,1,,268735022,785,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1463,1159580,2,1,,273002833,785,Inactive,,,,,"The chemical genetic matrix (CGM) dataset as reported in Wildenhain et al. (2015) Prediction of Synergism from Chemical-Genetic Interactions by Machine Learning. Cell Systems Volume 1, Issue 6, p383-395",Summary,,
1464,1159607,2,1,,312996697,785,Inactive,,,,,Screen for inhibitors of RMI FANCM (MM2) intereaction,Other,26962873.0,
1465,1159614,1,2,,170464661,785,Inactive,22328079.0,2581.0,,Potency,A Novel Cell-Based Assay to Identify Small Molecules for B -Galactocerebrosidase,Confirmatory,,
1466,1159620,1,1,,103176079,785,Active,,,,,Summary of drug indications.,Other,,
1467,1202488,1,1,,103176079,785,Active,,,19.46,IC50,Trypanosomicidal activity against epimastigote stage of Trypanosoma cruzi CL-B5 after 72 hrs by beta-galactosidase reporter gene assay,Confirmatory,25884114.0,
1468,1202489,1,1,,103176079,785,Unspecified,,,123.1,IC50,Cytotoxicity against mouse J774 cells assessed as cell viability after 48 hrs by resazurin assay,Confirmatory,25884114.0,
1469,1202490,1,1,,103176079,785,Unspecified,,,,,Selectivity ratio of IC50 for mouse J774 cells to IC50 for epimastigote stage of Trypanosoma cruzi CL-B5,Other,25884114.0,
1470,1224818,1,1,,312344702,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway - cell viability counter screen,Confirmatory,,
1471,1224819,1,1,,312344702,785,Inactive,325495545.0,2101.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
1472,1224820,1,1,,312344702,785,Active,325495545.0,2101.0,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway,Confirmatory,,
1473,1224821,1,1,,312344702,785,Inactive,325495545.0,2101.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
1474,1224822,1,1,,312344702,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) ### cell viability counter screen,Confirmatory,,
1475,1224823,1,1,,312344702,785,Inconclusive,325495545.0,2101.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC),Confirmatory,,
1476,1224834,3,1,,144209543,785,Inconclusive,,,30.451,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1477,1224834,3,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1478,1224834,3,1,,170464661,785,Inconclusive,,,33.4915,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library - cell viability counter screen,Confirmatory,,
1479,1224835,1,1,,144209543,785,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1480,1224835,1,1,,144210335,785,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1481,1224835,1,1,,170464661,785,Inactive,160794.0,,,Potency-Replicate_1,qHTS assay to identify small molecule inhibitors of firefly luciferase,Confirmatory,,
1482,1224836,1,1,,144209543,785,Inconclusive,,,54.1504,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1483,1224836,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1484,1224836,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1485,1224837,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1486,1224837,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1487,1224837,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway - cell viability counter screen,Confirmatory,,
1488,1224838,1,1,,144209543,785,Inactive,66775687.0,9970.0,24.1881,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1489,1224838,1,1,,144210335,785,Inactive,66775687.0,9970.0,30.6379,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1490,1224838,1,1,,170464661,785,Inactive,66775687.0,9970.0,10.5909,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1491,1224839,1,1,,144209543,785,Active,66775687.0,9970.0,30.451,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1492,1224839,1,1,,144210335,785,Active,66775687.0,9970.0,34.3762,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1493,1224839,1,1,,170464661,785,Inconclusive,66775687.0,9970.0,14.9601,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway,Confirmatory,,
1494,1224840,3,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1495,1224840,3,1,,144210335,785,Inconclusive,,,34.3762,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1496,1224840,3,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library - cell viability counter screen,Confirmatory,,
1497,1224841,3,1,,144209543,785,Inactive,325495545.0,2101.0,24.1881,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1498,1224841,3,1,,144210335,785,Inactive,325495545.0,2101.0,15.3553,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1499,1224841,3,1,,170464661,785,Inactive,325495545.0,2101.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1500,1224842,3,1,,144209543,785,Inconclusive,325495545.0,2101.0,24.1881,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1501,1224842,3,1,,144210335,785,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1502,1224842,3,1,,170464661,785,Inactive,325495545.0,2101.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library,Confirmatory,,
1503,1224843,1,1,,144209543,785,Inconclusive,119601739.0,7253.0,43.0132,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1504,1224843,1,1,,144210335,785,Inconclusive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1505,1224843,1,1,,170464661,785,Inconclusive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1506,1224844,1,1,,144209543,785,Inconclusive,,,54.5984,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1507,1224844,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1508,1224844,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway - cell viability counter screen,Confirmatory,,
1509,1224845,1,1,,144209543,785,Inconclusive,344243002.0,100757539.0,50.1697,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1510,1224845,1,1,,144210335,785,Inconclusive,344243002.0,100757539.0,56.6363,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1511,1224845,1,1,,170464661,785,Inconclusive,344243002.0,100757539.0,39.0762,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX,Confirmatory,,
1512,1224846,1,1,,144209543,785,Inconclusive,11995455.0,3091.0,61.2604,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1513,1224846,1,1,,144210335,785,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1514,1224846,1,1,,170464661,785,Inactive,11995455.0,3091.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway,Confirmatory,,
1515,1224847,1,1,,144209543,785,Inconclusive,,,126.021,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1516,1224847,1,1,,144210335,785,Inconclusive,,,44.9878,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1517,1224847,1,1,,170464661,785,Inconclusive,,,55.1965,Potency-Replicate_1,qHTS assay to identify small molecule agonists of H2AX - cell viability counter screen,Confirmatory,,
1518,1224848,3,1,,144209543,785,Inactive,325495545.0,2101.0,10.8044,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1519,1224848,3,1,,144210335,785,Inactive,325495545.0,2101.0,19.3312,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1520,1224848,3,1,,170464661,785,Inactive,325495545.0,2101.0,11.8832,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1521,1224849,3,1,,144209543,785,Active,325495545.0,2101.0,8.5823,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1522,1224849,3,1,,144210335,785,Active,325495545.0,2101.0,21.6899,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1523,1224849,3,1,,170464661,785,Active,325495545.0,2101.0,13.3332,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library,Confirmatory,,
1524,1224857,2,1,,170464661,785,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1525,1224857,2,1,,312344702,785,Inconclusive,,,22.3872,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human iPSC derived neural progenitor cells (hNPCs),Confirmatory,,
1526,1224859,2,1,,90340863,785,Inactive,,,,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1527,1224859,2,1,,170464661,785,Inconclusive,,,12.5893,Potency,qHTS assay for measurement of the activity of small molecule inhibitors on Zika virus induced Caspase-3 activity in human astrocytoma cells,Confirmatory,,
1528,1224863,1,1,,316919235,785,Inactive,90421313.0,1080.0,,IC50,Phenotypic Assay to Identify Small Molecules that Upregulate Production of hCFTR in HeLa Cells,Confirmatory,,
1529,1224867,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1530,1224867,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1531,1224867,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 24 hour,Confirmatory,,
1532,1224868,1,1,,144209543,785,Inconclusive,,,4.8661,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1533,1224868,1,1,,144210335,785,Inconclusive,,,5.4941,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1534,1224868,1,1,,170464661,785,Inconclusive,,,5.3538,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 32 hour,Confirmatory,,
1535,1224869,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1536,1224869,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1537,1224869,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 0 hour,Confirmatory,,
1538,1224870,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1539,1224870,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1540,1224870,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 40 hour,Confirmatory,,
1541,1224871,1,1,,144209543,785,Inconclusive,,,54.5984,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1542,1224871,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1543,1224871,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 40 hour,Confirmatory,,
1544,1224872,1,1,,144209543,785,Inconclusive,,,6.126,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1545,1224872,1,1,,144210335,785,Inconclusive,,,15.4845,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1546,1224872,1,1,,170464661,785,Inconclusive,,,11.9856,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 16 hour,Confirmatory,,
1547,1224873,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1548,1224873,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1549,1224873,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 8 hour,Confirmatory,,
1550,1224874,1,1,,144209543,785,Inconclusive,,,3.8653,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1551,1224874,1,1,,144210335,785,Inconclusive,,,3.8895,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1552,1224874,1,1,,170464661,785,Inconclusive,,,4.7716,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 40 hour,Confirmatory,,
1553,1224875,1,1,,144209543,785,Inconclusive,,,54.5984,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1554,1224875,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1555,1224875,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 24 hour,Confirmatory,,
1556,1224876,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1557,1224876,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1558,1224876,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 16 hour,Confirmatory,,
1559,1224877,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1560,1224877,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1561,1224877,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 32 hour,Confirmatory,,
1562,1224878,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1563,1224878,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1564,1224878,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 24 hour,Confirmatory,,
1565,1224879,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1566,1224879,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1567,1224879,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 40 hour,Confirmatory,,
1568,1224880,1,1,,144209543,785,Inconclusive,,,54.5984,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1569,1224880,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1570,1224880,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 0 hour,Confirmatory,,
1571,1224881,1,1,,144209543,785,Inconclusive,,,54.5984,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1572,1224881,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1573,1224881,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 32 hour,Confirmatory,,
1574,1224882,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1575,1224882,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1576,1224882,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 0 hour,Confirmatory,,
1577,1224883,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1578,1224883,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1579,1224883,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 32 hour,Confirmatory,,
1580,1224884,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1581,1224884,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1582,1224884,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 8 hour,Confirmatory,,
1583,1224885,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1584,1224885,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1585,1224885,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 16 hour,Confirmatory,,
1586,1224886,1,1,,144209543,785,Inconclusive,,,6.126,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1587,1224886,1,1,,144210335,785,Inconclusive,,,7.7606,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1588,1224886,1,1,,170464661,785,Inconclusive,,,8.4852,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 24 hour,Confirmatory,,
1589,1224887,1,1,,144209543,785,Inconclusive,,,54.5984,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1590,1224887,1,1,,144210335,785,Inconclusive,,,24.5412,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1591,1224887,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HEK293 cells - 8 hour,Confirmatory,,
1592,1224888,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1593,1224888,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1594,1224888,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HEK293 cells - 16 hour,Confirmatory,,
1595,1224889,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1596,1224889,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1597,1224889,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS RealTime-Glo MT Cell Viability Assay in HepG2 cells - 0 hour,Confirmatory,,
1598,1224890,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1599,1224890,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1600,1224890,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,A CellTox Green Cytotoxicity Assay to monitor cytotoxicity in HepG2 cells - 8 hour,Confirmatory,,
1601,1224892,1,1,,144209543,785,Active,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1602,1224892,1,1,,144210335,785,Active,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1603,1224892,1,1,,170464661,785,Active,66775687.0,9970.0,,,qHTS assay to identify small molecule agonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1604,1224893,1,1,,144209543,785,Inconclusive,66775687.0,9970.0,14.4079,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1605,1224893,1,1,,144210335,785,Inconclusive,66775687.0,9970.0,28.3743,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1606,1224893,1,1,,170464661,785,Inconclusive,66775687.0,9970.0,11.8832,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the constitutive androstane receptor (CAR) signaling pathway: Summary,Summary,,
1607,1224894,1,1,,144209543,785,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1608,1224894,1,1,,144210335,785,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1609,1224894,1,1,,170464661,785,Inactive,11995455.0,3091.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the hypoxia (HIF-1) signaling pathway: Summary,Summary,,
1610,1224895,1,1,,144209543,785,Inconclusive,119601739.0,7253.0,13.602,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1611,1224895,1,1,,144210335,785,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1612,1224895,1,1,,170464661,785,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1613,1224896,1,1,,144209543,785,Active,344243002.0,100757539.0,41.4103,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1614,1224896,1,1,,144210335,785,Active,344243002.0,100757539.0,50.4772,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1615,1224896,1,1,,170464661,785,Active,344243002.0,100757539.0,37.605,Ratio Potency (uM),qHTS assay to identify small molecule agonists of H2AX: Summary,Summary,,
1616,1224905,2,1,,121361200,785,Inactive,120997.0,25643.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1617,1224905,2,1,,121361200,785,Inactive,74356043.0,55704.0,,,High-throughput screen for inhibitors of the GIV GBA-motif interaction with Galpha-i G protein subunits,Screening,,
1618,1225511,1,1,,103176079,785,Unspecified,,,10.0,IC50,Cytotoxicity against human A549 cells after 48 hrs by MTT assay,Confirmatory,25710081.0,
1619,1225512,1,1,,103176079,785,Unspecified,,,10.0,IC50,Cytotoxicity against human K562 cells after 48 hrs by MTT assay,Confirmatory,25710081.0,
1620,1225513,1,1,,103176079,785,Inactive,38258633.0,23411.0,,,Increase in SIRT1 (unknown origin) deacetylation activity at 10 uM,Other,25710081.0,
1621,1259241,1,1,,144209543,785,Inconclusive,,,17.1239,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1622,1259241,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1623,1259241,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol - cell viability counter screen,Confirmatory,,
1624,1259242,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1625,1259242,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1626,1259242,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881 - cell viability counter screen,Confirmatory,,
1627,1259243,1,1,,144209543,785,Inactive,124375976.0,367.0,30.451,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1628,1259243,1,1,,144210335,785,Inactive,124375976.0,367.0,30.6379,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1629,1259243,1,1,,170464661,785,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881,Confirmatory,,
1630,1259244,1,1,,144209543,785,Inconclusive,348019627.0,2099.0,30.451,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1631,1259244,1,1,,144210335,785,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1632,1259244,1,1,,170464661,785,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol,Confirmatory,,
1633,1259247,1,1,,144209543,785,Inconclusive,124375976.0,367.0,36.8922,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1634,1259247,1,1,,144210335,785,Inconclusive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1635,1259247,1,1,,170464661,785,Inactive,124375976.0,367.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the androgen receptor (AR) signaling pathway using the MDA cell line in the presence of 0.5 nM R1881: Summary,Summary,,
1636,1259248,1,1,,144209543,785,Inconclusive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1637,1259248,1,1,,144210335,785,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1638,1259248,1,1,,170464661,785,Inactive,348019627.0,2099.0,,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen receptor alpha (ER-alpha) signaling pathway using the BG1 cell line in the presence of 0.1 nM 17-beta-estradiol: Summary,Summary,,
1639,1259310,1,1,,321942706,785,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1640,1259310,1,1,,332950281,785,Inactive,,,,,AlphaScreen-based biochemical high throughput primary assay to identify activators of the E3 ligase (FBW7).,Screening,,
1641,1259344,1,1,,144203720,785,Inactive,,,,Potency,qHTS assay to identify small molecule phospholipidosis (PLD) inducers,Confirmatory,,
1642,1259354,1,1,,348449361,785,Inactive,534286618.0,,,,Small-molecule inhibitors of ST2 (IL1RL1),Screening,,
1643,1259355,1,1,,17389853,785,Inconclusive,,,0.0251,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-1,Confirmatory,,
1644,1259356,1,1,,144203720,785,Inactive,,,,Potency,qHTS assay to identify small molecule inhibitors of chordoma cells - UCH-2,Confirmatory,,
1645,1259364,1,1,,144209543,785,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1646,1259364,1,1,,144210335,785,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1647,1259364,1,1,,170464661,785,Inactive,1013403374.0,9734.0,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors,Confirmatory,,
1648,1259365,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1649,1259365,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1650,1259365,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule HDAC inhibitors - cell viability counter screen,Confirmatory,,
1651,1259366,1,1,,144209543,785,Active,,,10.8044,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1652,1259366,1,1,,144210335,785,Active,,,24.3365,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1653,1259366,1,1,,170464661,785,Active,,,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1654,1259367,1,1,,144209543,785,Active,,,30.451,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1655,1259367,1,1,,144210335,785,Active,,,54.4827,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1656,1259367,1,1,,170464661,785,Inconclusive,,,18.8336,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway - cell viability counter screen,Confirmatory,,
1657,1259368,1,1,,144209543,785,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1658,1259368,1,1,,144210335,785,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1659,1259368,1,1,,170464661,785,Inactive,109731339.0,2737.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1660,1259369,1,1,,144209543,785,Active,109731339.0,2737.0,4.3013,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1661,1259369,1,1,,144210335,785,Active,109731339.0,2737.0,2.169,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1662,1259369,1,1,,170464661,785,Active,109731339.0,2737.0,6.6824,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway,Confirmatory,,
1663,1259370,2,2,,124636924,785,Inactive,312803.0,1017.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1664,1259370,2,2,,124636924,785,Inactive,510604.0,890.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1665,1259370,2,2,,124636924,785,Inactive,14602917.0,994.0,,,Inhibitors of CDC25B-CDK2/CyclinA interaction,Other,,
1666,1259377,1,1,,144209543,785,Inconclusive,54288833.0,2100.0,19.2133,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1667,1259377,1,1,,144210335,785,Inconclusive,54288833.0,2100.0,61.1306,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1668,1259377,1,1,,170464661,785,Inconclusive,54288833.0,2100.0,26.6032,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1669,1259378,1,1,,144209543,785,Inconclusive,54288833.0,2100.0,54.1504,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1670,1259378,1,1,,144210335,785,Inconclusive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1671,1259378,1,1,,170464661,785,Inactive,54288833.0,2100.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway,Confirmatory,,
1672,1259379,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1673,1259379,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1674,1259379,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1675,1259380,1,1,,144209543,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1676,1259380,1,1,,144210335,785,Inconclusive,,,43.2771,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1677,1259380,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1678,1259381,1,1,,144209543,785,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1679,1259381,1,1,,144210335,785,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1680,1259381,1,1,,170464661,785,Inactive,124375976.0,367.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist,Confirmatory,,
1681,1259382,1,1,,144209543,785,Inconclusive,,,68.1713,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1682,1259382,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1683,1259382,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway - cell viability counter screen,Confirmatory,,
1684,1259383,1,1,,144209543,785,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1685,1259383,1,1,,144210335,785,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1686,1259383,1,1,,170464661,785,Inactive,348019627.0,2099.0,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist,Confirmatory,,
1687,1259384,1,1,,144209543,785,Inconclusive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1688,1259384,1,1,,144210335,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1689,1259384,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen,Confirmatory,,
1690,1259385,1,1,,144209543,785,Inconclusive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1691,1259385,1,1,,144210335,785,Inconclusive,119601739.0,7253.0,76.9588,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1692,1259385,1,1,,170464661,785,Inactive,119601739.0,7253.0,,Potency-Replicate_1,qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway,Confirmatory,,
1693,1259386,1,1,,144209543,785,Inconclusive,,,68.1713,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1694,1259386,1,1,,144210335,785,Inconclusive,,,68.5896,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1695,1259386,1,1,,170464661,785,Inactive,,,,Potency-Replicate_1,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist - cell viability counter screen,Confirmatory,,
1696,1259387,1,1,,144209543,785,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1697,1259387,1,1,,144210335,785,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1698,1259387,1,1,,170464661,785,Inactive,124375976.0,367.0,,,qHTS assay to identify small molecule agonists of the androgen receptor (AR) signaling pathway in the presence of an antagonist: Summary,Summary,,
1699,1259388,1,1,,144209543,785,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1700,1259388,1,1,,144210335,785,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1701,1259388,1,1,,170464661,785,Inactive,1013403374.0,9734.0,,Antagonist Potency (uM),qHTS assay to identify small molecule HDAC inhibitors: Summary,Summary,,
1702,1259389,1,1,,124636924,785,Inactive,,,,,HIV1_TAR : FRET assay measuring displacement of FAM and TAMRA-labeled Tat peptide from HIV-1 TAR RNA.,Screening,,
1703,1259390,1,1,,144209543,785,Inconclusive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1704,1259390,1,1,,144210335,785,Inconclusive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1705,1259390,1,1,,170464661,785,Inactive,109731339.0,2737.0,,,qHTS assay to identify small molecule agonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1706,1259391,1,1,,144209543,785,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1707,1259391,1,1,,144210335,785,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1708,1259391,1,1,,170464661,785,Inactive,348019627.0,2099.0,,,qHTS assay to identify small molecule agonists of the estrogen receptor alpha (ER-alpha) signaling pathway in the presence of an antagonist: Summary,Summary,,
1709,1259392,1,1,,144209543,785,Active,109731339.0,2737.0,3.16423,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1710,1259392,1,1,,144210335,785,Active,109731339.0,2737.0,4.32771,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1711,1259392,1,1,,170464661,785,Active,109731339.0,2737.0,6.68242,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the sonic hedgehog signaling (Shh) pathway: Summary,Summary,,
1712,1259393,1,1,,144209543,785,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1713,1259393,1,1,,144210335,785,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1714,1259393,1,1,,170464661,785,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists or antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway - wild type cell line counter screen: Summary,Summary,,
1715,1259394,1,1,,144209543,785,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1716,1259394,1,1,,144210335,785,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1717,1259394,1,1,,170464661,785,Inactive,54288833.0,2100.0,,Ratio Potency (uM),qHTS assay to identify small molecule agonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1718,1259395,1,1,,144209543,785,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1719,1259395,1,1,,144210335,785,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1720,1259395,1,1,,170464661,785,Inactive,119601739.0,7253.0,,Ratio Potency (uM),qHTS assay to identify small molecule antagonists of the thyroid stimulating hormone receptor (TSHR) signaling pathway: Summary,Summary,,
1721,1259396,1,1,,144209543,785,Inconclusive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1722,1259396,1,1,,144210335,785,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1723,1259396,1,1,,170464661,785,Inactive,54288833.0,2100.0,,,qHTS assay to identify small molecule antagonists of the estrogen receptor beta (ER-beta) signaling pathway: Summary,Summary,,
1724,1259400,1,1,,170464661,785,Inactive,166209887.0,59350.0,,,qHTS Assay for Antagonists of the Relaxin Receptor RXFP1,Screening,,
1725,1259401,1,1,,144209543,785,Inconclusive,325495545.0,2101.0,24.1881,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1726,1259401,1,1,,144210335,785,Inconclusive,325495545.0,2101.0,21.6899,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1727,1259401,1,1,,170464661,785,Inconclusive,325495545.0,2101.0,18.1246,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1728,1259402,1,1,,144209543,785,Inactive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1729,1259402,1,1,,144210335,785,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1730,1259402,1,1,,170464661,785,Inconclusive,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor signaling pathway with the pleiotropic PPARgamma coactivator (PGC) from Tox21 10K library: Summary,Summary,,
1731,1259403,1,1,,144209543,785,Inconclusive,325495545.0,2101.0,9.266910000000001,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1732,1259403,1,1,,144210335,785,Inconclusive,325495545.0,2101.0,15.956,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1733,1259403,1,1,,170464661,785,Inconclusive,325495545.0,2101.0,11.8832,Antagonist Potency (uM),qHTS assay to identify small molecule antagonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1734,1259404,1,1,,144209543,785,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1735,1259404,1,1,,144210335,785,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1736,1259404,1,1,,170464661,785,Active,325495545.0,2101.0,,,qHTS assay to identify small molecule agonists of the estrogen related receptor (ERR) signaling pathway from Tox21 library: Summary,Summary,,
1737,1259407,1,1,,363898664,785,Active,,,,,CCRIS mutagenicity studies,Other,,
1738,1259408,1,1,,363895387,785,Active,,,,,GENE-TOX mutagenicity studies,Other,,
1739,1259409,1,1,,363898664,785,Unspecified,,,,,CCRIS tumor inhibitor studies,Other,,
1740,1259410,1,1,,363898664,785,Unspecified,,,,,CCRIS tumor promotion studies,Other,,
1741,1259423,1,2,,354827053,785,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
1742,1259423,1,2,,354986212,785,Inactive,,,,,Primary cell-based high-throughput screening assay for identification of small molecule agonists of Aedes aegypti NPYLR7 [Small Molecule Inhibitors of Mosquito Biting Behavior],Screening,,
